The effect of immune stimulation and immune suppression on experimental pre-invasive and early invasive carcinoma of cervix by McDicken, Ian Wilson
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
THE EFFECT OF IMMUNE STIMULATION A N D  IMM UNE SUPPRESSION 
O N  EXPERIMENTAL PRE-INVASIVE A N D  EARLY INVASIVE CARCINOMA
OF CERVIX.
A THESIS SUBMITTED BY ;
IAN W ILSON McDICKEN, M .B .,  Ch.B 
FOR THE DEGREE OF 
DOCTOR OF MEDICINE 
OF THE
UNIVERSITY OF GLASGOW
DEPARTMENT OF PATHOLOGY 
UNIVERSITY OF LIVERPOOL 
APRIL 1977.
ProQuest Number: 10646092
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uesL
ProQuest 10646092
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346

ACKNOWLEDGEMENTS
The experimental work for this thesis was started in the laboratories 
of Professor K . A .  Porter, The Department of Pathology, St. Mary's 
Hospital Medical School, London, and continued in the laboratories of 
Professor M . de Vries, The Department of Experimental Pathology, Erasmus 
University, Rotterdam, Holland. For the provision of laboratory facilities, 
encouragement and critical advice, 1 thank them.
Thanks are also due to Professor D . W.  van Bekkum, T . N . O . ,  Rijswlk, 
Holland, for the freely donated anti-lymphocyte serum, and to Dr. Cohen, 
Rijks Institut Voor de Volksgezondheid, Utrecht, Holland, for the equally 
freely supplied B . C . G .
1 acknowledge with thanks the expert technical assistance ably given 
by Mevrouw Anne Kri|gsman-Walsh. The manuscript was speedily and 
accurately typed by Mrs. Lynn Briscoe and I thank her for the manner in 
which she applied her skill.
During this time my w ife , Mora g, showed tolerance and forbearance 
coupled with enthusiastic support and for this 1 especially thank her.
SUMMARY
This thesis comprises a study of the pre-invasive and early 
invasive phases of a chemically induced carcinoma of uterine cervix, 
and the effects on the course of development of these of immune 
stimulation with Bacille Cal mette-Guerin or immune suppression with 
anti-lymphocyte serum.
The aims of the experiments are to investigate the effects of 
immune stimulation or immunosuppression on ;
(1) the time from carcinogen implantation to the detection of the 
first malignant cells by cytology, and
(2) the progression or regression of the various stages of pre­
malignancy and early malignancy in the suggested progression : 
normal -> moderate dysplasia -> severe dysplasia and /  or 
carcinoma in-situ -> carcinoma, with and without the continuing 
presence of the carcinogen.
Part I describes the experimental model and the reasons for its use. 
The model is a variation of that first described by Murphy in which, in 
mice, carcinoma of cervix Is induced by inserting a thread, with a knot 
at one end impregnated with a carcinogen-beeswax mixture, through the 
cervical canal so that the impregnated knot rests against the cervix. The 
main reasons for using this model are : -
(1) It gives a more reproducible incidence of tumours in the cervix 
than other methods, such as painting with carcinogen.
(2) The development of the lesions can be followed and staged
by the use of exfoliative cytology. This allows B . C . G ,  o r A . L . S .  
to be given at a stage in the development when some definite 
pathological change in the progression to malignancy can be 
demonstrated. This avoids the necessity of giving the agents blindly, 
or the complications that might arise from the use of traumatic biopsy 
as a means of estimating the stage of development.
(3) To reduce the complications due to the presence of the carcinogen, 
such as any immunosuppressive effect, the thread can be cut and the 
carcinogen removed. This also minimises any continuing carcinogenic 
effect such as might occur in short duration experiments in which large 
doses of carcinogen are given, with the result that the carcinogenic 
effect continues after the effect of immune stimulation has ceased. It 
also reduces the possibility of a massive carcinogenic effect over­
whelming more subtle alterations in the immune status.
Part 1 also describes the experimental design which essentially consists 
of two groups of experiments, in the first of which the carcinogen remains in 
position throughout the experiment and In the second of which the carcinogen 
is removed as soon as the first cytologically malignant cells are detected.
A . L . S .  or B . C . G .  are given when, in individual mice, a recognised stage 
in the development of carcinoma Is reached.
Part II reviews the literature regarding A.L .S .  emphasising the 
variable aspects of its effect on cellular and humoral immune responses 
to various antigens, and to different types of allografts , in differing 
strains and species of animals, where these have a bearing on tumour 
immunity. Also emphasised is the fact that many experiments have been 
performed without control groups using normal serum, compatible with 
the A . L . S . ,  so that any toxic or antigenic stimulatory effect of the serum 
constituents may be missed.
Part 111 reviews the literature regarding B . C . G .  and immune 
stimulation, and emphasises the numerous possibilities for varying immune 
responses to B . C . G .  such as strain differences, preparation differences, and 
genetic drift in the bacteria, and variable human and animal responses in 
the recipients, and how these can affect the comparison and interpretation 
of experimental results.
Part IV  gives details of the preliminary experiments. The first 
correlated the cytological findings with the histological appearances In the 
progression to carcinoma in the experimental animals and demonstrated that 
within the limits of the experiment the cytological findings accurately 
reflected the histologic appearances. The second demonstrated that the 
tumours produced in the cervix by this technique were immunogenic and 
demonstrated a difference in the antigenic strength of the tumours produced 
by the two methods.
Part V gives the results obtained which can be summarised as :
(1) There is no alteration in the length of time from the implantation 
of the carcinogen to the detection of the first cytologically 
malignant cells in any groups.
(2) The length of time from implantation to invasion is little altered 
in the experimental groups where the carcinogen remains in 
position, but that where the carcinogen is removed B . C . G .  
increases and A . L . S .  decreases the pre-invasive stage.
(3) Where the carcinogen remains in position the epithelium does not 
revert to normal in any group but remains cytologically malignant.
(4) A . L . S .  increases and B.C.G.  decreases the number of tumours 
resulting from the pre-invasive stages where the influence of the 
carcinogen is removed.
(5) B . C . G .  will arrest the progression of some early invasive lesions, while
from this stage, A . L . S .  increases the resulting number of tumours, in
those experiments where the carcinogen has been removed.
Part VI discusses the results in relation to other experiments.
in t r o d u c t io n
Although the specific immunising potency of methylcholanthrene
induced tumours of mice had been suggested earlier the first
convincing demonstration of immunity to methyl cholanthrene induced
tumours in Inbred mice, was the destruction of the tumours following
(2 )ligation of their blood supply . Shortly after comparable findings
( 3 )
were demonstrated with methyl cholanthrene Induced rat sarcomas 
The immune specificity to the transplanted sarcoma neoantigens was 
demonstrated by the finding that tumour immunised mice could still 
accept d<in grafts from the tumour donor thus removing the possibility 
of the involvement of an alloantigenic immune response and the 
demonstration that resistance to tumour re-implantation could develop 
in the autochthonous host excluded the possibility that the immunity could
(5)be accounted for by residual heterozygosis
Since then a large number of chemically Induced tumours have been 
shown to be antigenic and many of these tumours have been used to 
analyse the Involvement of tumour-host interactions in the process of
(7 8)oncogenesis, and to demonstrate the effects of host immune stimulation '
or immunosuppression on subsequent tumour growth.
Little has been reported on the effect of manipulation of the immune
(II 12,13)
response on Identifiable pre-invasive stages of carcinoma development ' '
although in some studies immune stimulation or immunosuppression has been 
started blindly at times when malignant clones of cells might be expected to 
be present, but before outgrowth of these has occurred
Clin ically large numbers of lesions thought to precede invasive
carcinoma of cervix have been detected by the use of exfoliative cytology,
and it has been concluded that only about 25 -  30%  of these pre-invasive
lesions w ill progress to an invasive phase Evidence has also been
produced that pre-cancerous lesions of the bronchi disappear, in ex-smokers,
within five years of giving up smoking
Whether immunological factors are involved in the development and
progression or regression of these lesions is unknown, but the high incidence
of pre-invasive cervical lesions found in renal transplant patients undergoing
immunosuppressive therapy and the suggested immunodepressive effect of 
(19)cigarette smoking , suggests that they may be a factor. Premalignant and 
malignant skin tumours also appear to be greatly increased in immunosuppressed 
patients^ and experimentally there is some evidence that very early 
chemically induced premalignancies of liver may often be suppressed immuno-
1 • I I  ( 1 3 )logically
The object of the experiments described in this thesis is to consider any 
modification of the development, progression or regression of cytologically 
demonstrated pre-invasive or early invasive cervical lesions, by non-specific 
immune stimulation using Bacille Calmette-Guerin ( B . C . G . )  or immuno­
suppression using anti-lymphocyte serum (A.L.S. ) .
Part I
EXPERIMENTAL MODEL A N D  REASONS FOR ITS USE
After the demonstration of the carcinogenic properties of crude
(21)tar attempts were made to induce carcinoma of cervix in mice by
the instillation or implantation of crude tar into the vaginal vault or 
(22 23)
cervix ' . O nly a few invasive carcinomas resulted from these
experiments the lesions often regressing despite continued application 
of the tar.
Experimental induction of malignant tumours by the use of crude
tar was eventually replaced by more refined methods utilising pure
compounds possessing potent carcinogenic properties which resulted in
higher yields of epidermoid carcinomas. The intravaginal instillation
of a 1% solution of 3 , 4 benzpyrene in acetone induced a high incidence
of carcinoma of cervix in H mice and painting the cervix, under
direct vision through a speculum, resulted in an even greater yield of
(25)tumours with a shorter latent period
Accurate sustained placement of the carcinogen in the uterine cervix 
resulting in a more constant incidence of carcinoma was attained by 
inserting a thread saturated in methyl cholanthrene into the cervical canal
( O A)
under direct vision , and this technique has been used subsequently
(27)to study the development of experimental carcinoma and pre-cancerous 
(28 29)
lesions ' of cervix, by histology and exfoliative cytology. We have 
adapted this model and used it in this study of the early lesions of experimental 
chemical carcinogenesis, and the effects thereon of non-specific immuno- 
stimulation and immunosuppression.
One advantage of using this technique is that the thread containing 
the carcinogen can be removed at any time thus reducing or eliminating 
any possible immunosuppressive effect of the carcinogen and allowing the 
development of the tumour without this factor complicating the experimental 
immunological manipulations. This is of importance since it not only 
reduces the risk of systemic immunosuppression, which can be detected and 
monitored, but it also reduces the possibility of local immunosuppressive 
activity, which may be of importance in the development of neoplasia and 
the effectiveness of any immune response to the tumour.
Using the uterine cervix as the organ for the induction of carcinoma 
by chemical agents also gives an advantage over other sites in that, with 
the use of exfoliative cytology, the early changes can be followed and 
studied by a non-traumatic, non-destructive process, in contrast to sequential 
biopsies which might, by removal of tissue, affect subsequent tumour 
development, or by causing an inflammatory reactior^ alter the immune 
response to the tumour.
Using exfoliative cytology the sequence of changes, normal -> 
dysplasia -> severe dysplasia and/or carcinoma in-situ -> invasive 
carcinoma, can be readily identified and followed ; the onset and duration 
'of these phases can be timed in relation to the date of implantation of the 
carcinogen, and neoplastic tumour formation can also be differentiated from 
inflammatory swelling with which it could be confused if  only palpation is 
used to determine tumour occurrence.
Removal of the carcinogen also has the advantage of producing a 
long latent period and slow growing tumours with a low growth fraction 
which approximate more closely to human tumours than most experimental 
models, e .g .  the subcutaneous injection of chemical carcinogens in 
animals tend to produce fast growing sarcomas which may have little  
relevance to most human tumours
Another advantage of this system is that the tumour induced is a 
carcinoma, occurring at a site which is a major problem in humans, and 
preceding which, in the cervical epithelium, all the pre-invasive changes
(31 )can be demonstrated which if  associated with cellular antigenic changes
might condition the host's subsequent immune response to the tumour, in
contrast to the injection of tumour cells into immunologically virgin animals.
The use of primary tumour in outbred hosts may also approximate more
closely to the variability and unpredictability characteristic of human neoplasms
and emphasises those features of immune surveillance, neoplastic progression
and spread which may be unique to undisturbed in-situ tumours, in contrast
to transplants of cultured tumour cells, or subcutaneous induced sarcomas.
It has been suggested from the results of experiments using pellets of 3 -
methyl cholanthrene in wax, implanted into the skin, that tumours induced
by low concentrations of oncogen may be good models of spontaneous neoplasms 
(32)
and this strengthens the hypothesis that some spontaneous tumours may 
develop from exposure to low levels of oncogen. In some of our experiments 
the attempt to reduce the total exposure to the carcinogen was made by 
removal of the carcinogen in the early stages of the neoplastic process, so 
that the exposure to the carcinogen is for a relatively short duration.
Materials and Methods
Animals Female virgin Swiss mice aged 6 - 9  weeks at the beginning of 
the experiment, and weighing about 30 gms were used. The mice were 
housed 5 per cage and given drinking water and purina chow ad libitum, 
and housed in temperature and light controlled rooms.
Carcinogenesis The carcinogen was 20 -  Methyl cholanthrene (Koch Light
Laboratories) suspended in beeswax in a ration 20 MG : Beeswax of 1 : 3 .
The carcinogen was applied using a slight modification of a technique 
(2A\
first described by Murphy . Sterile No. 10 cotton threads, knotted by a
triple loop, 1 cm from one end, were impregnated with the carcinogen-beeswax
mixture by dipping the knot into the melted mixture using forceps. The lengths
of thread on either side of the knot were protected from contamination with the
mixture by the blades of the carrying forceps. The threads were weighed before
+and after impregnation and only threads carrying -  0 .25  mg carcinogen were 
used.
Blunt pointed tapestry needles were used to carry the thread.
Using ether anaesthesia, deep enough to obtain complete relaxation, 
with the dorsum of the left hand against the back of the mouse and the tail 
held between the left thumb and forefinger, pulling the tail sufficiently to 
arch the back over the dorsum of the hand, exposed the vagina and allowed 
the insertion of the tip of the needle. With sufficiently deep anaesthesia the 
needle could readily be inserted into the cervix without trauma, passed 
through the lateral horn of the uterus and out through a small incision in the
left flank. The end of the thread was anchored in the subcutaneous 
tissues so that the carcinogen impregnated knot was maintained in 
contact with the uterine cervix. The skin incision in the left flank was 
closed with metal clips. The I cm length of thread distal to the knot was 
trimmed so that no thread hung out of the vagina, but enough remained 
in the vagina to enable traction to be applied in those experiments in
which it was desired to remove the thread.
In some experiments the carcinogen was maintained in position 
throughout the experiment, in other experiments the carcinogen was 
removed as soon as evidence of severe dysplasia or in-situ carcinoma was 
detected by exfoliative cytology. The removal was performed by cutting 
the thread at its subcutaneous anchorage and pulling it out via the vagina. 
Anti-lymphocyte serum (A.L .S . )
The A . L . S .  was supplied by Professor Van Bekkum of the Radiobiological 
Institute, T . N . O . ,  Rijswijk, Holland, and had the following characteristics : 
Cytotoxicity against lymph node cells 1 : 64
Cytotoxicity against thymus cells I : 1024
Mean survival time for allogeneic skin transplant with I ml A . L . S .  : 14 days. 
Total protein : 61.5 mg/ml
Albumen : 29 .8  %
a Globulin : 25.1 %
P Globulin ; 29 .9  %
y Globulin : 15.9 %
Details of the dose schedule are given under the e>^erimental design heading.
Bacille Calmetfe-Guerin ( B . C . G . )
Lyophilised B . C . G .  was used. The B . C . G .  was injected s.c.  in a 
dose of 0 .3  mg dry weight, suspended in 0 .3  ml sterile pyrogen free water 
and contained -  160,000,000 living b ac te ria /m l. The time of injection 
varied according to the experimental groups and details are given under the 
experimental design.
Cytology
Cytological specimens were collected weekly starting 2 weeks before 
the implantation of the carcinogen and continued throughout the experiments. 
The specimen was collected using a Pasteur pipette shortened by breaking the 
narrow stem close to the body of the pipette. The sharp edges of the broken 
end were flame rounded. Normal saline, 0 .5  ml, was installed into the 
vagina, withdrawn, and this was repeated three times. The fluid was 
transferred to a small centrifuge tube, lightly centrifuged and slides prepared 
from the deposit. The preparations were stained with Haematoxylin and 
Eosin, and Papanicolau stains.
Histology
The uterus a n d /o r tumour were removed en bloc. If no tumour was 
present the uterus was blocked intact and sectioned at 3 p. Every tenth 
section was stained by Haematoxylin and Eosin, The lesions present in these 
cases were classified as Normal ; mild dysplasia ; severe dysplasia ; in-situ 
carcinoma and early invasive carcinoma. Early invasive carcinoma was 
defined as histological invasion with no demonstrable tumour formation.
When tumours were present, blocks taken from the tumours were sectioned at 
3 p and stained with Haematoxylin and Eosin.
The Design and Aims of the Experiments,
There are two main groups of experiments :
(a) Those in which the carcinogen remained in position throughout the 
experiment. These experiments were terminated six months after the 
implantation of the carcinogen (ST Experiments).
(b) Those in which the carcinogen was removed at the first evidence of 
severe dysplasia or in-situ carcinoma as detected by exfoliative 
cytology, i . e .  when the first cytologically malignant cells were 
detected. These experiments were terminated twelve months after 
the implantation of the carcinogen (IT  Experiments).
ST Experiments
The experiments in which the carcinogen remained in position
throughout were divided into the following groups :
ST Group 1) A . L . S .  or B . C . G .  was started on Day -  14 relative
to the day of carcinogen implantation, in randomly 
grouped mice.
ST Group II) In this group A . L . S .  or B . C . G .  was started on the
day of carcinogen implantation, in randomly grouped
mice.
ST Group 111) This group consisted of mice with changes of in-situ
malignancy or severe dysplasia. Individual mice 
were randomly grouped at the time the first 
cytologically malginant cells were detected, i . e .  at 
the beginning of in-situ carcinoma or severe dysplasia 
in that mouse, and A . L . S .  or B . C . G .  given.
ST Group IV) This group consisted of mice which showed
cytological evidence of early invasion. Individual 
mice were randomly grouped at the time the earliest 
cytological signs of invasive carcinoma, without any 
palpable or visible tumour, were detected in that 
mouse, and A. L . S .  or B . C . G .  given.
The A. L . S .  was given in an initial dose of 0.25 ml 1,P. on days 0 , 2, 
5, and 7 and then 0.25 ml l .P.  weekly for the subsequent three months.
B . C . G .  was given in one dose of 0 .3  mg dry weight, suspended in
0 .3  ml sterile pyrogen free water.
N . H .  S. was used as one control on a schedule and dosage identical to
A . L . S .  Saline injection 0 .3  ml was given as a control for the B . C . G .  
experiments.
Cytology was performed weekly starting three weeks before carcinogen 
implantation.
The aims of these experiments were
1) To detect any variation in the time of first detection, by cytology, of 
malignant cells in groups ST I and ST I I ,  i . e .  to determine whether
A. L . S.  immunosuppression or B . C . G .  immunostimulation accelerated 
or delayed the appearance of malignant cells, and thus the onset of 
in-situ carcinoma or severe dysplasia.
2) In groups ST 1 and ST II to determine if  the administration of A . L . S .  or
B . C . G .  affected the length of time from carcinogen implantation to 
the time of invasion as detected by cytology.
3) To detect any variation in the number of tumours produced by the 
administration of A . L . S .  or B . C . G .  when these agents are given 
at an identifiable stage of development, in the suggested 
progression from normal to carcinoma via either dysplasia or in-situ 
carcinoma, i . e .  Group STI,  at a time when the epithelium is 
normal. Group STII at implantation at the initial early inflammatory 
stage consistent with mild dysplasia. Group ST III on the detection of 
severe dysplasia or in-situ carcinoma, and in Group ST IV  on the 
detection of early invasive carcinoma.
4) If any variation occurs, to demonstrate histologically if the alteration 
in the number of tumours produced is, in the B . C . G .  group, due to 
arrest at some stage In the progression from normal to carcinoma or Is 
due to complete destruction of malignant cells and regression of the 
changes to normal, and in the case of A . L . S . ,  if any enhancement 
of tumour growth occurs, is it due to A . L . S .  acting preferentially
at some stage in the early development of invasive carcinoma or is it 
a late acting phenomenon, affecting mainly the rate of growth of the 
tumour.
LT Experiments
The experiments, in which the carcinogen was removed on the first 
detection of malignant cells by cytological examination, were divided as 
follows
LT Group 1) In this group A . L . S .  or B . C . G .  was started in
randomly grouped animals when the carcinogen was 
implanted. The carcinogen was removed when the 
first malignant cells were detected.
LT Group 2) In this group, at the time the first malignant cells
were detected by exfoliative cytology, the carcinogen 
was removed, the animals randomly grouped andA. L .S .  
or B . C . G .  started,
LT Group 3) This group consisted of animals that three months after
the removal of the carcinogen showed cytological 
evidence of severe dysplasia or in-situ carcinoma only.
The animals were randomly grouped and A . L . S .  or 
B . C . G .  started.
LT Group 4) This group consisted of animals that three months after
the removal of the carcinogen showed cytological 
evidence of early invasion only, without any palpable 
or visible tumour. The animals were randomly grouped 
and A. L . S .  and B . C. G.  started.
The controls in all the groups were animals receiving N . H . S .  or saline 
injections in the same schedule and amounts as the A . L . S .  or B . C . G .  
respectively. The A . L.S.  and N ,  H. S. were given In an in itia l dose of 0 .25  ml
l .P.  on days, 0 , 2 , 5 and 7 and then weekly for the next three months.
B . C . G .  was given in one dose of 0 .3  mg, dry weight suspended in 0 .3  ml 
sterile pyrogen free water.
Cytology was performed weekly starting three weeks before carcinogen 
implantation.
The aims of these experiments were
1 In groups LT I and LT2 to detect any variation In the time of first detection by 
cytology of malignant cells due to A . L . S .  immunosuppression or B . C . G .  
immunostimulation, i . e .  to the onset of severe dysplasia or In-sItu carcinoma.
II In groups LT 1 and LT2 to determine if A . L . S .  immunosuppression or
B . C . G .  immunostimulation affect the length of time from carcinogen 
implantation to the earliest evidence of invasion as detected by 
cytological examination.
III To determine the effect of A . L . S .  or B . C. G.  on the progression or 
regression of pre-invasive lesions such as severe dysplasia or in-situ 
carcinoma, where these agents are given before removal of the carcinogen 
(Group LT I), at the time of removal of the carcinogen (Group LT2) or 
three months after removal of the carcinogen (Group LT3).
IV To determine the effect of A . L . S .  or B . C. G.  on the subsequent course 
of early invasive carcinoma when these agents are given to animals 
showing cytological changes consistent with early invasive carcinoma 
only,three months after the removal of the carcinogen (Group LT4).
V If A .  L.S, or B . C . G .  did have any effect to determine whether, in the
B . C . G .  groups, this is due to arrest of development at some particular 
stage or reversal to normal, and in the A .L .S .  groups at what stage 
facilitation of tumour growth occurs.
Part 11
ANTI-LYMPHOCYTE SERUM IMMUNOSUPPRESSION A N D  CHEMICAL 
CARCINOGENESIS.
INTRODUCTION : THE IMMUNOSUPPRESSIVE EFFECT OF A. L . S .
Although knowledge of the immunosuppressive action of anti­
lymphocyte serum has been relatively recently acquired, similar sera have
been used since the end of the nineteenth century. The first recorded
(33 34)applications by Metchnikoff '  were during the investigation of the
cellular basis of inflammation. Since then sporadic reports have anticipated
much of our current knowledge, such as the demonstration that A . L . S.
agglutinated and killed lymphocytes in vitro, and that its cytotoxicity
could be destroyed by heating the serum to 55°C . for thirty minutes^^^^ .
Species specificity and the ability to cause a leukopenia in vivo were also
demonstrated. Some of the early sera failed to discriminate among leukocytes 
37^
‘  , but later lymphocyte specific anti-sera were demonstrated. Strong
inhibition of the skin reactions of delayed hypersensitivity to tuberculin in 
guinea pigs by A . L . S .  was shown, and these findings confirmed and 
extended to the prolongation of skin homograft survival and to the inhibition
(41)of auto-immune disease . With the combination of thoracic duct drainage 
a n d A . L . S . ,  striking prolonged skin graft survival was obtained This
demonstration was followed by work establishing A . L . S .  as the most potent 
inhibitor of the experimental transplant rejection reaction
and as it is suggested that the mechanism of rejection of tumours is 
similar to the mechanism of transplant rejection 49)^
knowledge of the mode of action of A . L . S .  and experience of its 
immunosuppressive activity under various experimental conditions 
are necessary for the critical understanding and interpretation of its 
effects on tumour growth.
A . L . S ,  injection in both animals and man is followed by a 
decrease in the number of circulating lymphocytes the lymphopenia
(51)being proportional to the injected dose and appearing to be a specific 
effect of A . L . S .  since it is only very slightly altered by adrenalectomy, 
and normal serum from the same donor species causes no lymphopenia, 
suggesting that stress from the serum injection plays no part. The lympho­
penia appears to be due to a direct or indirect complement dependent
cytocidal activity 53)  ^ The degree of lymphopenia appears to bear
(54 55)no direct relationship to the immunosuppressive activity ' although 
occasional dissenting observations have been made
The early descriptions of the histological modifications of the lymphoid 
organs by A . L . S .  are somewhat confusing due to the differences in experimental 
conditions, animal species, quality and purity of the anti-serum and lack of 
distinction between specific and non-specific effects of A . L . S .
It is now generally agreed that the fraction of A . L . S .  responsible for
immunosuppression produces quite selective morphological alterations in the
, , . . (57, 58, 59, 60) . l • , ,lymphoid organs . The most prominent change is a marked
depletion of small lymphocytes from the para-cortical areas of the 
lymph node and the peri-arteriolar cuff of the spleen, i . e .  the thymus 
dependent areas^^^. In contrast, germinal centres and medullary areas 
of the lymph nodes and follicular areas of the spleen are as a rule 
unaffected by A . L . S . ,  and even after prolonged treatment the thymus 
is not significantly altered histologically^^^^
After chronic A . L . S .  administration however, lymphoid depletion
can be obscured by hyperplasia and hypertrophy of germinal centres,
ges were conside 
(44, 45, 62, 63)
(55)
medullary and follicular zones , and these chang red
originally to be specific features induced by A . L . S ,
Since, however, these changes are not observed in animals previously 
rendered tolerant to the foreign protein in the serum it is suggested that 
these features are non-specific and represent the morphological equivalent 
of the immune response of the recipient to the heterologous proteins 
constituting A . L . S .  à5)^
That A . L . S .  is a potent immunosuppressive has been affirmed by 
demonstrating its inhibitory effect on an extensive array of immune phenomena.
Although attempts to prolong skin allograft survival by A. L . S.  
had previously been made, the first really significant results showing the 
immunosuppressive activity of A . L . S .  in this situation were obtained by 
Woodruff and Anderson who were able to prolong the survival of
first set skin allografts in rots across a strong histo-compatibility barrier.
These findings have since been confirmed by many investigators and extended
. (43, 68, 69, 70, 71) , ,, -, . , .to many species and skin allograft survival is the
most common assay of immunosuppressive activity of anti-sera employed
r . . , (72, 58)for experimental purposes
The immunosuppressive effect is most evident when anti-serum is
started prior to grafting, and can be further increased if the injections
are continued after transplantation (43/73,74)^ but the effect can also
/ y  c y z \
be apparent if the anti-serum is given after grafting '
The activity of A . L . S .  as an immunosuppressant has also been 
confirmed in whole organ transplantation (77,78,79) impression
gained from the reports on organ transplants in larger mammals and humans 
is that the effects have not been as dramatic as those achieved with skin 
grafts in rodents This may be due to genetic, technical or other
complicating factors or to the proportionately smaller doses of A . L . S .  
which the larger animals tolerate and which are usually employed, although 
other factors such as humoral antibody damage may be more important 
in chronic allograft damage to whole organs. This may be of importance 
in the interpretation of results of A . L . S .  administration on tumour growth 
since it is not known whether tumours behave as whole organs or as skin 
grafts.
In addition to the ability to prevent or delay the onset of cell 
mediated immunological reactions leading to the rejection of homografts and 
to arrest those already in progress, A . L . S .  is also capable of inhibiting other 
cell mediated immune responses. An important example of this phenomenon
is the graft versus host ( G . V . H . )  reaction which results when immuno­
competent cells, capable of reacting against the host, are injected 
into recipients incapable of rejecting them. In various experimental 
systems which leads to G . V . H .  reaction, the immunosuppressive 
effect of A . L . S .  has been demonstrated, e.g.  the injection of parental 
strain cells into F 1 hybrids , or the transfer of allogeneic
lymphoid cells to neonatal or irradiated animals
(39)Since the first report there has been extensive confirmation of 
the ability of A . L . S .  to suppress the dermal manifestations of delayed 
hypersensitivity Although inhibition of non-specific inflammation
may play a role, the most likely explanation for the reported reduction of 
responsiveness and decreased mononuclear infiltrate at the site of challenge 
is the reduction of potentially reactive cells.
The induction and expression of delayed hypersensitivity to such
antigens as tuberculin, ovalbumen, diphtheria toxoid, dinitro-chloro benzene
. , (58, 87, 88, 89, 90) , .  ^ ,and oxazolone can also be prevented.
Whereas the immunosuppressive effect of A . L . S .  on cell mediated 
responses is fairly general in most species, irrespective of the type of 
experimental condition, the same does not appear to be true for humoral 
antibody production where a number of factors, especially type and 
dosage of antigen, animal strain and species seem to play major roles in 
determining the final result.
An immunosuppressive effect of A . L . S .  has been demonstrated on 
the antibody response to sheep erythrocytes in mice ^^^and rats^^^'^^^,
(43 95)to bacterial antigens in mice and dogs '  , and to soluble proteins in
mice and rats^^^' A . L . S .  apparently interferes more readily with the
humoral antibody response to thymus dependent antigens such as sheep
(97)
erythrocytes and bovine albumen, although this is still disputed
The genetic constitution of the animals seems to have an important
influence on these immunosuppressive effects ; immune reactions in Sprague-
Dawley rats are not inhibited by A . L . S .  in contrast to Wistar rots and
mice o f t h e C . B . A .  or A ,  strains are much more sensitive to A . L.S. than 
(97)
H strain . These findings are obviously of importance where Sprague-
Dawley rats or C^H mice are used in experiments designed to demonstrate
the effect of A . L.S.  in carcinogenesis, but they also suggest that other strains
will have a greater or lesser response that must influence the interpretation
of the results and warn against direct comparisons.
Doses of A . L . S .  capable of suppressing the primary humoral response
(98 99)fail to have a pronounced effect on the secondary humoral response 
and other differences of effect on humoral and cellular responses were shown 
when a course of A . L . S .  capable of eliminating the immune memory to a 
second set skin graft was unable to return a sensitised animal to virgin 
reactivity as regards B.S.A.
A number of hypotheses have been proposed to explain the immuno­
suppressive activity of A . L . S .
The first theory to be advanced was based on the in-vitro cytotoxic 
activity of A . L . S .  and on the evidence of the observed lymphopenia and 
cellular depletion of lymphoid organs of A . L . S .  treated animals 
Some observers also noted that the return to a normal immune reactivity, 
after discontinuance of injections, was coincident with the reappearance 
of normal levels of circulating lymphocytes and of normal histology on 
lymphoid organs However, marked lymphopenia is not a constant
feature , nor does its degree have any correlation with the level of 
immunosuppression induced, and it can be of much shorter duration than 
the period of immune suppression.  ^ Other procedures giving comparable 
or even greater lymphopenia, such as steroid injections or thoracic duct 
drainage do not induce equivalent immunodépression.
Another mechanism by which A . L. S. might act is that, by coating 
the lymphocyte membrane, A . L . S .  might prevent any interaction between 
antigen and its specific r e c e p t o r t h u s  blocking an essential step of the 
immune response. However, this 'blindfolding* hypothesis could not be 
reconciled with the observations that immune incompetence after A . L . S .
treatment persists in conditions where repeated lymphocyte divisions have
essi\
(52)
occurred nor does it explain the non-suppr ive activity of A . L . S .
antibody fragments which also coat lymphocytes
It has also been suggested that A . L . S .  might act by interfering with 
thymic hormone however, this theory appears untenable since
the effects of A . L . S .  and thymectomy are strongly synergistic^^^^' 105)
‘Sterile activation' was proposed on the basis of the finding of
hypertrophic, hyperplastic lymphoid tissue, containing large numbers
of blast cells, in A . L . S .  treated animals This theory postulates
that A . L . S .  may induce a generalised, but non-immunologically
productive, activation of lymphocytes, which would preclude any other
immunological reactivity. Transforming ability is, however, shared by
a wide variety of agents, none of which can compete with A . L . S .  as an
immunosuppressive and F (ab)^ antibody fragments of A . L . S . ,  which
(52)are immunological I y inert, are able to produce blast transformation
The increased number of blast cells after A . L . S .  treatment are mostly
the consequences of A . L . S .  Immunogenlcity and this proliferative response
(55)is reduced in animals tolerant to A . L . S .
Evidence accumulating in the last few years leads to the conclusion 
that the mechanism of A . L . S .  immunosuppressive activity is mediated through 
the inactivation of a selected subpopulation of cells, comprising the 
recirculating lymphocyte pool,
It is important to emphasise that the histological modifications 
induced by A . L . S .  are the same as those resulting from thymectomy 108) 
or thoracic duct drainage conditions that lead to depletion of the
members of the long lived, recirculating thymus dependent lymphocyte pool, 
suggesting that A . L . S .  has a similar effect.
There are also similarities in the characteristics of A . L . S .  immuno­
suppression and that induced by thymectomy both of which impair the host's 
ability to mount a cell mediated response and thymectomy synergises
with A .L.S .therapy The return to normal immune reactivity
after A . L . S .  treatment is slow and thymus dependant \  and lymphoid 
cells obtained from A . L . S .  treated animals show a reduction in the 
elements bearing the -O- antigen which is known to be a marker
for thymus derived lymphocytes. They also lose their ability to respond 
-vitrc
(114)
to in- o P . H. A.  a property known to pertain to thymus derived
cells
Current knowledge therefore indicates that A . L . S .  inactivates the 
members of the long lived thymus derived population with a slow turnover, 
continuously re-circulating via the lymph and blood through the lymphoid 
organs and periphery.
The action of A . L . S .  in depleting the circulatory pool of long lived 
lymphocytes, containing the cells involved in the inductive, and effector, 
phases of graft rejection as well as the elements endowed with immunological 
memory for cellular reactivity, explains the major immunosuppressant effect 
on cell mediated responses, whereas only some humoral antibody responses 
are involved. The importance of this on the influence of A . L . S .  on tumour 
formation, is that the most important inhibitory immune responses to tumours 
appear to be cell mediated through thymus dependant lymphocytes, 
although this is not certain for the pre-malignant or pre-invasive stages.
If immunological factors are of importance in the control of neoplasia, it 
follows that depression of this system, especially thymus-dependent (T) 
immune responsiveness, should facilitate tumour development, and it is 
well established in viral oncogenesis that thymectomy at or near birth leads
to an increased tumour incidence^^^^' 118)^  Similarly selecti ve
immunosuppression with anti lymphocyte or antithymocyte serum markedly
u  . u  .  ■ • ( 1 1 9 ,  1 2 0 ,  1 2 1 )enhances the response to oncogenic viruses
Although the aetiological factors in the formation of the tumours
are unknown,in patients 256 recipients of transplants have developed
(122)
de novo malignancies , out of a suggested population at risk of 12,389
(123)undergoing immunosuppression therapy after receiving a transplant ,
The most common epithelial lesions are the various carcinomas of skin and 
lips, 39%, and various stages of carcinoma cervix, 8%, of the to ta l. 
respectively, with lymphomas forming 27%. These figures suggest that 
patients immunosuppressed for organ transplants have an increased risk of 
developing certain malignancies, and that host factors, possibly immunological, 
are involved.
The influence of immunosuppression on chemical carcinogenesis 
is less clear-cut than in viral oncogenesis. After the report that neonatal 
thymectomy significantly reduced host immunocompetence it was
claimed that thymectomized mice developed more skin tumours when treated 
with benzo (a) pyre ne However, others failed to observe any marked
influence of thymectomy on the induction of skin papillomas or carcinomas 
following repeated skin painting with MC and also failed to show any
difference in skin tumorigenesis in intact or newborn thymectomized mice 
following Initiation with an oral dose of urethan and promotion by skin- 
painting croton o il .
There are similar discrepancies in the reports on the influence of 
thymectomy on the carcinogenic response to subcutaneous injections of 
polycyclic hydrocarbons. It was suggested that neonatal thymectomy of 
C 57 BL mice rendered them more susceptible at the young adult stage to 
a subcutaneous dose (200 pg) of M C, as manifested by a reduction of latent 
induction period in thymectomized mice so that, at 14 weeks, 78% had 
developed sarcomas compared with 42% of sham-thymectomized control 
mice However, the final incidence of sarcomas in both groups was
similar, approaching 100%, and there was no difference in the growth rates 
of the tumours evaluated from the time taken to develop from small (5 mm) 
nodules to a mean diameter of 15 mm.
An enhanced response to MC in inbred AKR and outbred CF 1 mice,
fl28)but not inbred C^H mice following neonatal thymectomy was also reported
In the sensitive strains, tumours arose more rapidly whereas in AKR mice the
final tumour incidence was increased from 70% to 100%
However, in other studies neonatal thymectomy of C 5 7 BL mice did not
markedly enhance susceptibility to MC carcinogenesis, and the incidence and
growth rates of tumours were not significantly different from those in controls 
(129 130)
' . Also, although thymectomy at 3 days of birth was reported to
shorten latent induction periods this was not observed in the previous
(129)
study where thymectomy was carried out at 24 hours and mice so treated 
had proven immunoi ncompetence as evidenced by their failure to reject skin 
allografts. The most consistent feature arising from these studies was the 
increased immunogenicities of the sarcomas arising in thymectomized mice as
qualitatively revealed by showing that resistance could be induced in
syngeneic mice against transplants of 9 /1 0  tumours arising in thymectomized
mice, whereas only 5 /1 0  tumours from control, sham-thymectomized mice
(129)
had comparable immunogenicities
In the second of these studies comparison of the immune response
elicited against tumours arising in thymectomized and non-thymectomized mice,
by the rejection of a standard challenge dose of tumour cells, (10^), in normal
syngeneic mice immunized by tumour excision indicated significantly
increased immunogeni cities in tumours arising from a dose of 250 pg of M Cin
thymectomized mice compared with sham-operated controls. A 4 -  fold larger
dose of carcinogen, however, failed to enhance tumour immunogenicity in
thymectomized mice, suggesting that the variable influence of thymectomy on
MC -  carcinogenesis may be due to the immunosuppression induced by the
carcinogen which is known to be dose dependent
Neonatally thymectomized mice showed increased sensitivity to chemical
carcinogenesis in studies on lung adenoma formation after treatment with 7 , 12 -
(132 133)dimethylbenz (a) anthracene or urethan , and restoration of the
immunological competence of the thymectomized mice, by repeated thymus 
implantation, reduced the sensitivity to urethan, the number of lung adenomas 
per mouse being similar to that of intact controls
Reports of the effects of anti-lymphocyte serum ( A. L .S . )  immunosuppression 
on chemical and physical carcinogenesis show similar variation in the results. 
Since these reports are of most pertinence to the experiments reported in this 
thesis they are given here in some detail.
In mice, C . B . A .  strain , in which sarcomas were induced by
1.0 mg M . C . A .  injected subcutaneously. Rabbit A.L .S.  given in a
dosage of 0.25 ml twice per week, starting 6 days before
administration of the carcinogen, increased the incidence of tumours
(\ T
and decreased the latent period
In C 57 B L /6  J mice in which tumour induction was by 2 .0 mg M . C . A ,  
subcutaneous!>^0.25 ml. Horse A . L . S .  given twice per week for twelve 
weeks, starting 14 days after administration of the carcinogen, increased 
the incidence of tumours and decreased the latent period .
Tumours induced by 0 .05  mg M . C . A .  I .C .  in C.B.A,  x C57 BL/F, 
Hybrids had a decreased latent period and an increased growth rate when 
the mice were treated by either Horse or Rabbit A.L .S.  given I. P. in doses 
of 0 .5  ml once per week for five weeks or I ml twice per week for one week
followed by I ml once per week for eight weeks, starting on the day of
. , r . . (137)induction of carcinogenesis
In these three experiments the dosage of A .L .S .  used caused sufficient
systemic immunosuppression to delay allograft rejection.
In C^ Hf and I strain mice, a strain effect of anti-thymocyte globulin
( A . T . G . )  on tumour formation was demonstrated. Tumours were induced by
the administration of 0 .2  to 2 mg M . C . A .  subcutaneously, and 0 .25  ml of
a I :4 dilution of Rabbit A . T . G . given 1 .P. on the day of induction and
thereafter 3 times in the first week, followed by 0.25 ml once per week to the
end of the experiment. The incidence of tumours in strain 1 was increased,
n 38)
but there was no effect on the C^Hf strain mice . The immunosuppressive
effect of the A . T . G .  regimen was demonstrated in this experiment by
decreased graft v host reaction, decreased mixed lymphocyte culture
response and decreased anti-SRBC haemaglutinin titres. This finding
(97)
is in keeping with the low sensitivity of C^H mice to A . L . S ,  , but 
may also merely reflect the very high sensitivity of C^H strain mice to 
the carcinogenic effect of M . C . A .  or the marked sensitivity of C^H mice
to the immunosuppressive effect of M . C . A .  over which any effect of A . L . S .
■ U4. u • • I (139) m ight be m inim al
An effect of the amount of carcinogen applied was demonstrated by 
implanting subcutaneously into (C 5 7 BL/6 x BALB/C) hybrids M . C . A .  
impregnated discs containing 0 ,03  or 0,15 mg M . C . A .  Combined adult 
thymectomy and A. L . S .  (0.25 ml on days -  I ,  +1,3 and 5 in relation to the 
carcinogen implantation, day 0) resulted in increased tumour incidence with 
low dose M . C . A . , but no effect with the higher dose M . C . A .  . In 
these experiments the immunosuppressive effect of the A.L.S. / thymectomy  
regime was demonstrated by delayed allograft rejection and increased growth 
of M . C . A .  tumour transplants. These results might reflect persistance of the 
effect of the high dose of M . C . A .  at the time the immunosuppressive effect 
of A . L . S .  was diminishing,
Syrian hamsters, treated with Rabbit A . L . S .  1 ml I .P.  in itia lly , 
followed by 0 .45  ml three times per week for nine weeks, starting 6 weeks 
after the carcinogen application, had a larger number of tumours induced by 
the application of 0 . 5% D . M . B . A .  on the cheek pouch than control animals. 
The application was three times weekly. Histologically the tumours induced
in the A . L . S .  group were more undifferentiated and invasive than those 
of the control group. Unfortunately in this experiment the immunosuppressive 
effect of the A . L . S .  used was only tested in vitro, and the in vivo effect 
of the regimen was not tested. Nor was the effect of N . R . S .  demonstrated 
In a similar experiment Rabbit A . T . S . ,  0 .25  ml S.C.  three times per 
week in one group, and 0.1 ml S.C.  three times per week in a second group, 
beginning I or 8 days before the application of 0 . 5% D . M . B . A .  to the 
hamster's cheek pouch, resulted in a shortened latent period and an increased 
number of tumours compared to a control group. The carcinogen was applied 
three times per week In this experiment, as in the preceding one, the in
vivo immunosuppressive effects of the A . T . S .  regime was not demonstrated 
nor was N . R . S .  used in one of the control groups.
Rabbit A . L.S . ,0 .5  ml I . P . ,  three times per week, in an experiment 
using the carcinogenic effect of painting 0 .5%  D . M . B . A .  in heavy mineral 
oil onto the buccal pouch of outbred Golden Syrian hamsters, resulted in a 
significant increase in the number of carcinomas compared to control groups 
receiving either N . R. S.  or no treatment. The carcinogen was painted onto 
the buccal pouch three times per week for 10 weeks. The efficacy of the
A . L . S .  therapy was determined by its ability to delay rejection of skin 
allografts and by its cytolitic effect on hamster thymocytes
Objections to these three experiments can be raised since the hamster 
buccal pouch is an Immunologically privileged siteXrefT) and results obtained 
using the immune manipulation of tumours induced in this site may not be 
generally applicable.
Studies investigating the influence of A . L . S .  -  induced immuno­
suppression on different stages of skin carcinogenesis by various carcinogens 
in mice have been reported. In a group of S.W.R.  mice using topical 
application of 1.5% D . M . B . A .  to the skin followed by promotion with 
croton oil twice per week to the end of the experiment, as the means of 
tumour induction, treatment with 0 .5  ml Rabbit A . T .  S. once per week had 
no effect on papilloma formation, but resulted in decreased papilloma 
regression and an increased progression from benign to malignant tumours 
The immunosuppressive effects of this dosage of A . T .  S. was demonstrated 
by delayed tumour allograft rejection.
2
Using ultra violet (UV) light, 2.82 mj/mm five times per week for 
30 weeks, as a source of physical carcinogenesis on the skin of H - 1 mice, 
it could be demonstrated that A . L . S .  given S.C.  at a dosage of O.l ml twice 
per week for 20 weeks starting 14 days before exposure to the UV light, 
resulted in greatly increased tumour incidence, increased numbers of tumours 
per mouse and a shortened latent period Unfortunately In this
experiment the Immunosuppressive effect of the A . L . S .  was not demonstrated 
nor were N . R. S.  controls used so that although the magnitude of the effect 
of A . L . S .  on UV light carcinogenesis was considerable, the conclusion that 
this was due to the immunosuppressive effect of A . L . S .  alone cannot be 
sustained in this experiment.
In DBA/2 mice, receiving -  0 .3  mg M . C . A .  applied to the skin three 
times per week for four weeks. Rabbit A . T. S ., 0 .5  ml I .P.  twice per week 
in the 1st and 3rd weeks after the start of carcinogen application, caused a 
slight decrease in the latent period of skin papillomas, but had no effect
on the leukaemia incidence The immunosuppressive effect of
the A . T . S .  was demonstrated by delayed allograft rejection.
In an attempt to bypass the systemic immunosuppressive effect of 
the M . C . A .  carcinogen, after the application of the M . C . A .  to the 
skin of BALB/C mice the skin was then transplanted to other BALB/C mice.
The mice with the skin graft were then treated with Rabbit A . L . S .  0.25 ml 
I .P.  daily for 7 days starting on the day of grafting. This resulted in a 
marked decrease in the regression of the papillomata and in this experiment 
histological evidence was also provided that the regression of skin papillomata 
can be immunological ly mediated
Incipient tumours were produced by the administration of 5% 3 -  methyl-  
cholanthrene pellets each pellet containing 0.15 mg, in normal and immuno- 
depressed BALB/C mice. Immunodépression was achieved by thymectomy 
plus a regimen of rabbit anti-mouse lymphocyte serum. The A . L . S .  was given 
0.25  ml on days -  I ,  +1 and+ 3 relative to the implantation of the M . C . A .  and 
once weekly thereafter. After two months, half the animals in each group 
(normal and immunodepressed) were subjected to full thickness autografting 
of the area containing the M . C . A .  pel let.  The grafts were lifted from their 
graft bed and then replaced in their original position and secured by metal 
clips. No tumours developed in the autografted sites of normal mice. Normal 
mice with non-grafted sites and both groups of immunodepressed mice had 
significant tumour development The A . L . S .  immunosuppressive
potency was demonstrated against minor and major H - 2  incompatible graft 
combinations. Unfortunately, N . R . S .  was not used in a control group. This 
suggests that while they remain undisturbed, the developing lesions do not
stimulate an immune response which will eliminate the developing malignant 
cells, but that the inflammatory changes which are caused by grafting are 
sufficient to allow access of immune competent cells and that the resulting 
response w ill eliminate the developing malignant cells.
Repeated administration of rabbit anti-mouse lymphocyte serum 
(A . L .S . )  0,1 ml I .P.  weekly for first 10 weeks of life to Charles-River mice 
given 100 pg 7, 12 dimethylbenz (a) anthracene at birth, greatly reduced 
the mean survival time of mice, markedly increased the number of tumours, 
and shortened the latency period, compared to control groups receiving 
N. R. S .  in similar amounts, or control groups receiving only D . M . B . A .
Rabbit A . L . S . ,  0 .05  to 0.25 ml given once 1. P ., 0 to 50 days after 
birth, increased the incidence of malignant lymphomas, induced by 100 pg 
D . M . B . A .  given S.C.  in Charles River strain mice. In this experiment the 
immunosuppressive effect of the A . L . S .  regimen was demonstrated by 
decreased plaque forming cell response to S.R.B.C.^^^^^. However, the 
mice controlled by N . R . S .  in this experiment had an equally increased 
incidence of malignant lymphomas suggesting that the effect of A . L . S .  was 
not related to its immunosuppressive activity but was a non-specific effect 
due to the antigenic stimulus of the rabbit serum.
In a similar experiment. Rabbit A . L . S .  given I .P.  in o varying regimen, 
either O.l ml once per week for 10 weeks after birth, or 0 .05  ml or 0.1 ml 
doily for seven days or the first few weeks after birth,increased the incidence 
of lymphomata or lung tumours in Charles River strain mice given 100 pg 
D . M . B . A ,  subcutaneously. The immunosuppressive effect of the A . L . S.  was
again demonstrated by a decreased plaque forming cell response to 
Unfortunately, the effect of a control group 
receiving N . R . S .  was not investigated in the experiment. It is of 
interest, however, that the different schedules of A. L . S.  administration 
selectively affected the production of either lymphomas or lung tumours.
Rabbit A . T , S . ,  0 . 5 m l  I .P.  on days-  6 , - 4 , - 2 ,  0,  or 0 . 5  ml 
given once per week for four weeks then six bi-monthly injections 
beginning day -  I ,  relative to day of starting the carcinogen, increased 
the incidence and reduced the latent period of plasmacytomas induced 
in BALB/c mice by 0 .5  ml mineral oil given I .P.  once per month for 3 
months The immunosuppressive effect of the A. T .  S. was demonstrated
by decreased graft versus host reaction and delayed allograft rejection.
Rabbit A . T . S . , 0 . 2  ml twice per week s.c. from day -2 0  to day +10, 
relative to day of giving carcinogen, decreased the latent period and 
increased the incidence and number of lung adenomas per mouse induced 
by 0 .5  mg/gram Urethan I .P.  in Swiss mice. Similar results were obtained 
in SW%/J mice with identical carcinogen, dose, and rate of administration, 
but in which the Rabbit A .T  .S. was given as 0.1 ml s.c. three times per week 
from week - 4  to week+ 4 The immunosuppressive effect was 
demonstrated by delayed tumour allograft rejection, decrease in haemagluttinin 
and haemolysin titres and decreased peripheral blood leucocyte count during 
the experiment.
Horse A . T . S. ,  0 . 5  ml I .P.  on day - 3  and 0.25 ml twice per week for 
30 weeks increased the incidence of bladder tumours, but had no effect on 
neural tumours in CDF rots given M . N . U .  10 mg/Kg twice per week for
nine weeks I . V .  . The immunosuppressive effect of the A . T .  S. 
regimen was demonstrated by delayed allograft rejection during the 
experiment.
The incidence of pre-neoplastic liver lesions was increased, in 
rats receiving D . E . N . A .  as carcinogen at a dose of 8 mg/Kg per day 
for six weeks, by the injection of Rabbit A . L . S .  1 ml on day 0 followed
(13)by 0 .5  ml daily for six weeks I .P.  . The immunosuppressive effect of 
this regime was not tested and neither was the strain of rats used of the 
route of administration of the carcinogen given.
In a similar experiment rats received either a single dose of 10 mg 
of diethylnitrosamine ( D . E . N . A . )  /K g  24 hours after partial hepatectomy, 
followed by 2 ml of horse anti-rat A . L . S .  once weekly for six weeks or a 
carcinogenic regimen of 8 mg D . E . N . A  ./K g /d ay  together with 2 ml
A . L . S .  once weekly for six weeks. No difference in the number and size 
of the pre-cancerous lesions could be detected from those occurring i n the 
respective controls receiving N . H . S .  /  or no serum. However, when rats 
subjected through to the second procedure were further left untreated the 
rate of death from liver tumours in the A . L . S .  group was significantly 
enhanced as compared with the control groups If the effect of the
A . L . S .  on the neoplastic process is mediated by immune suppression then 
the results of this experiment indicate that the cells participating in liver 
carcinogenesis become immunogenic to the cellular immune system beyond 
the pre-cancerous stage of development.
In contrast to these experiments which demonstrated some effect of
A . L . S .  on chemical and physical carcinogenesis, an extensive analysis of
A . L . S .  on MC carcinogenesis in several strains of mice, reported that no
effect on the incidence or latent period in most strains of mice could
be demonstrated by the administration of 0 .25  ml Horse or Rabbit A . T . S .
four times per week, for one week, followed by 0.25  ml once per week
thereafter, the administration beginning on day 0 or day + 50 , relative
to the injection of the carcinogen. The carcinogen was M . C . A .  given
intramuscularly. This experiment used a large number of different strains
of mice (BIO.A. ,  B10.D2., BlO.129., BlO.C^H.,  BlO.c. ,  C57B1/10.,
A . B y . ,  A . SU. ,  H T H /A O ., A /W y Sn.) and in most strains there was no
(14)
effect on the latent period or tumour incidence . The immunosuppressive 
effect of the A . L . S .  was demonstrated by concurrent tumour allograft 
rejection.
Nor could any effect be demonstrated by the injection of 2 ml
A . L . S . , I . P .  on the lOOth day after the carcinogen on latency or incidence
(154)of tumours induced in Lewis rats after the injection of 10 mg M . C . A .  s.c.
In this experiment an immunosuppressive effect was only checked by a decrease 
in the lymphocyte count.
No effect on the incidence of tumours was shown in C57BL/6J mice 
given 2 .0  mg M . C . A .  subcutaneously following the administration of Rabbit
A . L . S .  s.c.  in a regimen of 0.1 ml three t imes per week for two or six weeks 
or continuously to the end of the experiment The immunosuppressive
effect of the A . L . S .  could be demonstrated by delayed allograft rejection.
It should be noted, however, that the amount of carcinogen used was very 
high and the incidence of tumours approached 100% suggesting the carcinogenic 
effect would overwhelm and obscure any effect of A . L . S .
In Buffalo strain rats. Goat A . T , S .  1.5 ml daily for thirty days 
starting day - 2  did not affect the incidence of mammary tumour 
development after they had received D . M . B . A .  10 mg per week for 
four weeks The immunosuppressive effect of the Goat A . T .  S.
was shown by delayed allograft rejection.
PART ill
B . C . G .  IMMUNE STIMULATION ANDCHEM ICAL CARCINOGENESIS.
Introduction
B . C . G .  was originally isolated by Ca I mette and Guerin at the 
Pasteur Institute of Lille through the progressive attenuation of a virulent 
strain of Mycobacterium Bovis.
Later the stimulating effect of B . C . G .  on the immune response to 
antigens ^^3,159)^ and its remarkable stimulating effect on the 
reticulo endothelial system were discovered. When stimulation of 
the reticulo endothelial system with Zymosan was demonstrated to be 
associated with prevention of tumour g r o w t h t h e r e  rapidly followed
the investigation of, and demonstration of, the inhibitory effect of B . C . G .
. (7, 162, 163, 164) on tumour growth
Experience gained from the use of B . C . G .  in protection against tuberculosis.
Before assessing the reported effects of B . C . G .  on carcinogenesis, it 
is of interest, and educative, to consider what has been learned from the 
extensive studies of its use in protection against tuberculosis, since even 
here the results are by no means conclusive, and the variations and causes 
of the variations, may be relevant to the interpretation of the results of 
investigations of the effect of B . C . G .  on tumour formation.
A ll cultures of B . C . G .  originated from the original strain derived by 
C almette and Guerin, but due to the differences in preparation, culture 
methods and genetic drift the strains are not now identical and B . C . G .  as
currently employed has the disadvantage of variability in strain 
characteristics leading to substantial differences in biological behaviour^^^^\
The results of B . C . G .  immunisation programmes against tuberculosis have 
been variable, and the variability appears to be explicable mainly by 
differences in the potency of the B . C . G .  vaccines used Another
suggested explanation has been that the degree of protection provided by 
B . C . G .  is greatest in areas where the incidence of tuberculosis is high 
presumably due to a booster effect of frequent contact with stimulating 
mycobacterial antigens This corresponds with studies from a community
free from tuberculosis and other mycobacterial infections where a steady and 
substantial decrease in the incidence of skin sensitivity could be demonstrated 
after B . C . G .  vaccination . In contrast to this, in another study,
tuberculin sensitivity was unchanged two months to five years after B . C . G .  
immunisation and there was little  difference in skin sensitivity resulting from 
the use of eleven different B . C . G .  vaccines Variations in potency of
vaccines derived from different strains have, however, been demonstrated in 
laboratory animals and also in studies in different human populations^^^^'^^^^,
the most immunogenic strain being the Pasteur, and the least immunogenic 
the Glaxo strain.
Further variable characteristics of different strains include : viability  
in rabbit, mouse and guinea pig spleens : Jensen intraderma I test in guinea pigs ; 
allergenicity in animals ; protection against tuberculosis in mice and guinea 
pigs ; size of bacilli ; colony morphology and enzyme characteristics and 
phenotype variations
Different types of preparation of B . C . G .  have markedly different 
effects on the type of immune response of the recipient. Fully viable 
B . C . G .  preparations (log phase cultures) caused blast transformation of 
lymphocytes, and cell proliferation with little  histological evidence of 
anitbody réponse, whereas lyophilised commercial preparations, which 
had low viab ility  and a high concentration of soluble antigenic material, 
induced a strong antibody response
In view of the variable characteristics exhibited by living strains of 
B . C . G .  the use of fractions of cell components has been advocated in an 
attempt to obtain standardised preparations. Extensive reviews of the 
properties of non-living B . C . G .  vaccines suggested that the bias in favour 
of living vaccines was unjustified since many experiments contained 
substantial methodological errors, the most common being the low dosage of 
non-living B . C . G .  not allowing for the effect of multiplication of the 
living organisms 175)  ^ Vaccines of non-living B . C. G . components
have had substantial activity in increasing resistance against isologous tumours, 
and micro-organisms, and have the advantage that at least some of the hazards
f  I- • • - j  j  7^6)of living vaccines are avoided
These variations in biological activity of B . C. G.  make comparisons of 
the effect of different B . C . G .  programmes on the protection against 
tuberculosis difficult to evaluate and similar problems with strain and test 
variations are like ly  to make equally difficult the interpretation and comparison 
of results of B . C . G .  immunotherapy or Immunoprophylaxis from different 
centres using different B . C . G .  vaccines and different schedules of vaccination, 
especially in these experiments where insufficient experimental detail is given.
The mechanism of immunity to tuberculosis is not known precisely 
and a variety of immune responses occur after B . C . G .  vaccination, but 
the two predominant cell types involved in B . C . G .  induced immunity to 
tuberculosis, the lymphocyte and the macrophage, appear also to be those 
involved in B . C . G .  augmented tumour immunity. Both B . C . G .  and the 
presence of a growing tumour will  transiently increase the number of bone 
marrow monocytes, and, at a time when the effect of either has disappeared, 
the combination of the two w ill continue to produce significantly greater 
numbers of monocytes This suggests that analysis of changes in these
cells, quantitative or qualitative, produced by B .C . G.  vaccination 
against tuberculosis, or B . C . G .  macrophage stimulation against other 
organisms, may be of importance in defining more precisely the changes of 
importance in the B . C . G .  induced réponse to neoplasia.
The demonstration of delayed hypersensitivity (DH.)by a positive skin
test to purified protein derivative (P.P.D. )  is recognised as signifying
/ ly p )
resistance to tuberculosis although subject to considerable objective 
variation.
In vitro confirmation of the role of delayed hypersensitivity in immunity 
(179)
to tuberculosis , has been provided by the demonstration that the degree 
of D . H .  of skin to purified protein derivative (P.P.D. )  of tuberculin, 
correlates with the logarithm of the lymphocyte transformation index. Further, 
it has been shown that skin test negative individuals have lymphocytes with low 
affinity receptors for tuberculin, while skin test positive invidiuals have 
lymphocytes with high affinity receptors Lymphocyte transformation with
high doses of antigen is therefore possible, even though the skin tests are 
negative.
It was formerly believed that cellular immunity in tuberculosis was 
due to long-lived macrophages gradually being activated and destroying 
the bacllli^^^^\ Using the presence of B -  galactosidase as a macrophage
3
marker, and tritiated thymidine (H -T) to assess D . N . A .  synthesis, most
of the mononuclear cells in tuberulous lesions in rabbits were shown to be
recent immigrants and local division did not contribute substantially to 
fl82)
their number . The presence of D . H .  correlated with monocyte entry 
into the tuberculous lesions. Both the tissue monocyte (macrophage) and 
the circulating monocyte have been shown to produce a substance highly 
active in stimulating human bone marrow granulocytic and mononuclear 
cell production in vitro^^^^\ These properties are particularly important, 
as local cellular division of macrophages in B . C. G.  lesions cannot explain 
this high local concentration.
Macrophages stimulated by B . C . G .  have increased ability to inhibit 
the growth of certain intracellular parasites^^^' 185)  ^ ^  quantitative effect 
has been shown in that the clearance of Listeria monocytogenes from the 
blood was increased substantially in mice receiving 4 x 10  ^ viable B . C . G . ;  
4 X 10  ^ B . C . G .  resulted in only a slight clearance effect The
resistance of liver and spleen to Listeria monocytogenes infection correlated 
with the maximal number of living B . C . G . ,  and rose in parallel with the 
development of cutaneous D . H .  W ith re-infection by B . C. G . there was 
an increase in resistance, i . e .  increased clearance of organisms from blood, 
and killing in liver and spleen. Local multiplication was important in 
producing this effect, since heat-killed B . C . G .  was the least effective and
only slightly better effect was noted in animals receiving isoniazid with 
B . C . G .  These results correlated with the development of cutaneous D.H.  
and with cytological changes in the peritoneal macrophages suggesting 
increased metabolic and enzymatic activ ity .
Immune aspects of B . C . G .  and tumour growth.
In carefully performed studies a weakly antigenic, immunogenic, 
hepatocarcinoma was cutaneously transplanted to guinea pigs. After 
métastasés to regional lymph nodes had occurred the guinea pigs were 
treated by intra-lesional injection of B . C . G .  Tumour rejection was 
associated with B . C . G .  mediated granulomatous reaction at both the 
tumour site and in the regional lymph nodes in which the predominant cell 
involved appeared to be the macrophage This is in agreement with
previous in vitro studies showing that ascites tumours and transplantable 
lymphomas may be destroyed by macrophages. In these experiments the 
B . C . G .  organisms were found to be associated with macrophages and not 
in direct contact with tumour cells, suggesting that it is stimulation of 
macrophage activ ity , rather than any effect of the B . C . G .  on the tumour 
cells, that is of importance.
Support for the importance of macrophage-mediated tumour is provided
, , . , , . , _ , , , (189, 190, 191, 192, 193)by recent experimental evidence on activated macrophages
Macrophages activated by peptone injections or by nematode infection inhibit
the growth of Walker carcinosarcoma cells in rats, if the macrophages are
activated 5 days before tumour cell injection Since the effect was not
decreased by irradiation, it implies that functionally intact lymphocytes are
(195)not required. The effect is lost when macrophages are incubated with a 
serum 'blocking' factor.
In a study using several rat tumours of varying immunogenicity, 
nude athymic mice (nu/nu) were injected subcutaneously with a 
suspension of tumour cells or tumour cells plus Progressive
growth was observed in all control animals, but in the animals receiving 
B . C . G . ,  complete inhibition of tumour growth occurred. These studies 
suggest that the B . C . G .  suppression of tumour growth Is not effected by 
a lymphocyte mediated response, but that it Is mediated by macrophages.
Mouse macrophages activated by toxoplasma, were able to k ill 
cells from the syngeneic sarcoma K . H . T . ,  and the B . A . L .B . / c  mammary
(193)adenocarcinoma E . M . T . - 6 .
Other intracellular micro-organisms for example, Besnoitia Jelllsoni 
and L. monocytogenes also activate macrophages. In addition both endo­
toxin and double stranded R . N . A .  cause murine peritoneal macrophages 
to become cytotoxic to certain neoplastic cell lines but materials such
as starch and thioglycollate media produce inflammation, but no macrcphage 
activation.
Activated macrophages have little  or no cytopathic effect against non­
transformed cells, which do not cause malignant growth when inoculated with
(192)syngeneic hosts and have a limited life  span in vitro
The presumed active site of the activated macrophage is the cell membrane 
since the macrophages adhere to the tumour cells, and after 24 hours of contact 
between, for example, macrophages and lymphoma cells, irreversible damage 
to the tumour cells occurs and If  the lymphoma cells are removed after contact, 
the macrophages are unable to damage subsequently added lymphoma cells. 
Phagocytosis was not involved in growth inhibition and occurred only after 
tumour cells were disintegrating.
Using differential centrifugation, a sedimentable sub-cellular 
fraction was obtained from B . C . G .  -  infected mouse livers which lysed 
mastocytoma cells in vitro more rapidly than the corresponding fraction 
from the livers of normal mice. This observation suggests that B . C . G .  
was able to augment the enzymatic activity of mononuclear cells in the 
liver
While activated macrophages may non-speciflcally kill tumour cells
(199)by cell surface activity, immunity to subsequent challenge is specific ,
and it has been shown that immunisation of guinea pigs with B . C . G .  plus
one of 2 antigenically distinct hepatocellular carcinomas did not protect
(200)against the other hepatocellular carcinoma
Specificity has also been shown for B . C . G .  induced granulomatous
responses  ^ the accelerated granulomatous response occurring only
when B . C . G .  sensitised rabbits are challenged with B . C . G . ,  but not when
other granuloma inducing organisms are used.
Current evidence suggests that the mechanism of B . C . G .  anti-tumour
activity is a 2 step phenomenon. The first step involves recognition of
B . C . G .  by the host defence system and is immunologically specific ; the
second step is a granulomatous reaction in which macrophages are mobilised
(202)and activated by lymphocyte activation products , produced by 
specifically immune T cells reacting with antigens of B . C . G . ,  and the 
activated macrophages subsequently effect the non-specific destruction of 
the neoplastic cells. Subsequent specific immunity may be due to increased 
numbers of immunologically competent lymphocytes being available for 
activation by tumour specific antigens.
(203)However, lymphocytes and serum from B . C . G .  treated
B . A . L . B . / c  mice were cytotoxic to S9I melanoma cells, but not to 
mammary carcinoma, 3 M .C . induced sarcoma or fibroblast target cells 
from B . A . L . B . / c .  mice. These results suggested a specific B . C . G .  
induced protection against S9l melanoma cells, possibly due to sharing 
cross reacting antigens. Similar findings were also reported of an 
antigenic relationship between B . C . G .  organisms and line 10 cells 
These findings were extended by the demonstration of cell surface antigens 
on line 10 hepatocarcinoma by immune electron microscopy using xenogeneic 
and syngeneic tumour specific antibodies and syngeneic B . C . G .  induced 
antibody, showing that there are common antigens between line 10 hepato- 
carcinoma cells and B . C . G .  organisms. This specificity was further 
confirmed  ^ ^^^by blocking experiments and absorption of specific antibody 
to B . C . G .  by the tumour cells.
Antibodies in sera from rabbits immunised with line 10 cells and from 
rabbits immunised with B . C . G .  both bound B . C . G .  and line 10 antigens. 
Inhibition experiments confirmed the specificity of the reactions and also 
showed that antigenic components are shared by B . C . G .  and extracts of 
Rous sarcoma cells . Whether the shared antigens are identical with
tumour specific antigens and whether they have a function in the outcome 
of immunotherapy remain open questions.
Inbred strain - 2  Sewoll Wright guinea pigs were treated and cured 
of line 10 hepatocarci noma by the administration of sub cellular components 
of Mycobacterium bovis strain B . C . G . ;53% of the newly born offspring
resisted repeated challenges with the tumour. 23.5%  of offspring of
mothers given B . C . G .  only, resisted tumour challenge and the disease
was attenuated in many others A ll control offspring from normal
untreated mothers succumbed to the tumour. Resistance was associated
with delayed cutaneous hypersensitivity reactions to tumour and
mycobacterial antigens. In vitro, it has been shown that lymphocytes from
both B . C . G .  immunised guinea pigs and tuberculin -  sensitive humans are
more efficient in lysing mastocytoma cells coupled with P.P.D.  than non--
(208)
immune lymphocytes . However, this does not appear to be the 
situation In vivo since the B.C.  G .  organisms and tumour cells are not 
in contact.
Complement dependent cytotoxic antibody to tumour cells has been 
demonstrated in the sera of strain - 2  guinea pigs whose tumours had been 
cured by B . C . G .  treatment .
This cross reactivity of B . C . G .  and antigens on tumour cells may 
also be related to the ability  of B . C . G .  under certain circumstances to 
enhance tumour growth since it is known that B . C . G .  increases antibody 
production and enhances cell mediated immunity. The enhancement of
tumour growth has been attributed to the formation of blocking antibody (210
2M , 212, 213) - .. . , (214, 215) , , , , ^
, or antigen-antibody complexes , but lymphocytes
(216 217)have also been shown to have stimulatory activity ' . I f  the 
antibodies produced against B . C . G .  react with tun our antigens to produce 
antigen-antibody complexes these may have a blocking effect on cell mediated 
cytolosis, or lymphocytes sensitised to B . C . G .  might respond to tumour
antigens by a stimulatory effect on the tumour cells. The first effect
could be of special importance in those experiments using commercial
lyophilised B . C . G . ,  with its high soluble antigen component, which
tends to produce antibody rather than a cellular response
Immunological stimulation of tumour growth has been observed
following the innoculation of B . C . G .  into man and laboratory animals.
B . C . G .  given l . V .  to rats enhanced rather than suppressed, pulmonary
(218)
growth of transferred cells from several weakly immunogenic tumours 
Facilitation of tumour growth by B . C . G .  was also demonstrated using a 
carcinogen-induced mammary tumour in rats
In guinea pigs, the growth of intra-muscularly transplanted hepato­
cellular carcinoma could not be suppressed by intra-lesional injection of
B . C . G .  and in animals previously vaccinated with B . C . G .  tumour growth 
was accelerated .
Acceleration of malignant melanoma in humans has been reported
(221 222)following the intra-lesional administration of B . C . G .  . I n  one
(221)case serum blocking factors developed and in another case the
development of stimulatory lymphocytes was correlated with the appearance
r , . (222)of new lesions
In some circumstances the enhancing effect of B . C . G .  appears to be 
dose dependant. Groups of C57B1/6J mice pretreated with either high dose 
(0.5 mg) B . C . G .  or low dose (0.005 mg) B . C . G .  were then injected with 
Bl6 melanoma cells. In mice pretreated with the high dose the tumour grew • 
at an accelerated rate, whereas with the lower dose the tumour grew at a
(223)reduced rate compared with control mice . This enhancement may
be due to the more rapid induction and a. greater intensity of the immune
response following injection of increased doses of B . C . G .
It should be noted however, that two phenotypes of the Montreal
strain of B . C . G .  derived by culture of one strain of B . C . G . ,  had opposite
effects on the early development of subcutaneous transplants of epithelial
carcinoma one accelerating,the other inhibiting,tumour growth.
Another aspect of B . C . G . 's action is the ability  of B . C . G .  to induce
the production of "unblocking sera” . Blocking sera contain substances,
A g - A b  complexes, abrogating in vitro observed cell mediated lymphocyte
cytotoxicity ; unblocking sera, when added to blocking sera, will reverse
this effect. B . C . G .  primed rats and rabbits immunised with tumour cells
(oo
under certain circumstances , were able to produce "unblocking" sera, 
probably due to alteration in the ratio of Ag : Ab produced when, 
"unblocking serum" was added to the "blocking serum".
B . C . G .  and the treatment of tumours.
Attempts have been made experimentally to treat established tumours 
either with B . C . G .  alone or with B . C . G .  tumour vaccines and tocpply the
resulting knowledge and experience to the treatment of patients.
r , . . (226, 227) . (228, 229) .  ^ (230, 231)Studies with guinea pigs , mice and rats
have demonstrated complete suppression of tumour growth when tumour cells
were mixed with B . C . G .  before injection into syngeneic recipients, whereas
injection of B . C . G .  and tumour cells at separate sites did not affect the
growth of the tumour.
Effective immunotherapy of established leukaemia, lymphoma, and 
(232 233)
sarcoma transplants ' has been observed in mice and rats after
the administration of B . C . G .  alone or in combination with irradiated,
viable or neuraminadase-treated tumour cells.
The growth of methylcholanthrene induced sarcoma was controlled
or suppressed by B . C . G .  given intravenously in rats and attempts at
additional immune stimulation by the addition of irradiated tumour cells
mixed with B . C . G .  failed to provide more effective control of post-excision
pulmonary métastasés.
Similarly, in a rat epithelioma system additional immunostlmulation
with irradiated Spl tumour cells mixed with B . C . G .  did not provide more
(235)effective control of pulmonary métastasés then intravenous B .C ,G .alone
In the hepatocarci noma model in guinea pigs, a vaccine containing
live tumour cells and B . C . G .  was effective in treating animals with an
intraderma I tumour burden of 10 to 10 cells but noffor animals with 10 cells 
(236, 237)
Comparison of the effect of a single dose (0.015 mgm/g) B . C . G .  administered
by different routes, on the growth of Bl6 mouse melanoma, showed that if B . C . G .
was given 10 days before tumour challenge a significant resistance to tumour
growth was observed regardless of the site of tumour challenge or the route of
B.C. G . administration. The effect was less marked if the B . C . G .  was given
after tumour implantation
Growth of intrapleurally injected cells of immunogenic methylcholanthrene
induced sarcomas and of an ascitic hepatoma was suppressed by intrapleural
(239)
injection of viable or radiation sterilised B . C . G .  vaccine . 200 or 500 pg
8moist weight of B . C . G .  (Glaxo strain) containing 3 x 10 viable 
organs ism per ml was effective given several days before or after tumour 
challenge.
B . C . G .  injected intravenously, subcutaneously or intraperitoneally 
was without influence on pleural tumour growths, l .P.  growth of these 
tumours was suppressed only by l .P.  injection of B . C . G .  In contrast no 
effect could be demonstrated using two other tumours which lacked 
significant immunogenicity.
In patients attempts to control the progression of established tumours 
by B . C . G .  alone or B . C . G .  tumour cell vaccines have been less successful 
than might have been hoped for in light of the results from animal experiments.
B . C . G .  given by scarification to four patients with metastatic 
malignant melanoma resulted in progression of the disease in three patients 
and one patient responding over a period of 2 .5  years^^^^^. In another 
series often patients with metastatic malignant melanoma B . C . G .
by scarification resulted in no conclusive evidence that the treatment was 
either beneficial or harmful. Treatment of seven patients with disseminated 
malignant melanoma by oral ingestion of B . C . G .  resulted in the lesions of 
three patients regressing, two progressing and no detectable change in the 
lesions of the other two
In one study B . C . G .  (0 .8  x 10  ^ viable bac illi, tice strain, in 0.1 ml) 
given by intradermal injection appeared to delay the progression of malignant 
lymphoma  ^ . In the control series 77% relapsed, within the follow-up
period of 6 -  8 years, with a mean time to first new lesions of 10.6 months.
O f the vaccinated patients 61% relapsed, with a mean time to first new lesions
of 25 . 9  months. In this study, however, the vaccinated patients were 
in remission longer than the un-vaccinoted at the time of inclusion in 
the tr ia l, and in general in malignant lymphomas the longer the remission 
the less likelihood of relapse. A larger proportion of the patients 
vaccinated had stage 1 disease (as opposed to stage 11, ïn the un-vaccinated), 
a larger proportion were women, and a larger proportion had a longer 
duration of disease before treatment, all of which are favourable 
prognostic factors.
Twenty-one patients with Philadelphia positive chronic myeloid 
leukaemia treated with B . C . G .  and cultured cells developed persistent 
delayed hypersensitivity to antigens of the target cells and the clinical 
impression was of benefit 245)^ However, this study was uncontrolled,
vaccination schedules were variable, and the cultured cells were later found 
to be lymphoid lines. The authors noted that the results were compatible 
with non-specific immu no stimulât ion since the presence of tumour specific 
antigen in the vaccine could not be proved.
Four of eleven patients, with surgically incurable malignant melanoma, 
without skin métastasés, treated by intradermal injections of a vaccine 
containing irradiated autochthonous tumour cells and B . C . G .  had
objective responses. Remission was associated with a modest tumour burden 
confined to subcutaneous and lyrr^h node métastasés.
However, no definite conclusions can yet be drawn from the data so 
far available as to the efficacy of either non-specific B . C . G .  or B . C . G . -  
tumour vaccine therapy in the treatment of established tumours due to the 
small numbers involved and to the bad experimental design in some cases.
The tumour load appears to constitute a limiting factor in immuno­
therapy. Systemic administration of B . C . G .  and Irradiated leukaemia
5 (232)
cells could only cure mice if  the tumour load did not exceed 10 cells
(237)Intralesional injection of B . C . G .  induced complete regression ïn 60%
of guinea pigs with intradermal hepatoma transplants weighing 95 mg, but
in less than 20% with tumours weighing 425 mg.
In view of the evidence that the number of tumour cells is of importance
in determining the immune system's ability  to reject tumours the reduction of
the tumour burden may allow B . C . G . 's augmentation of immunity to eliminate
4the remaining tumour cells. In mice s.c.  innoculation of 1 x 10 L .S.T.R.A.  
lymphoid leukaemia cells led to detectable systemic leukaemia in 7 days and 
death in 14 to 17 days. A  single treatment of B . C . N . U .  prolonged life span 
20 -  25% ; the addition of B . C . G .  increased survival with 50 to 100% of 
animals being 'cured* of leukaemia Best results were obtained if the
B . C . G .  was administered with minimal tumour burdens.
In contrast no favourable effect could be demonstrated in the N . O . V . A .  
rat leukaemia treated with B . C . G . ,  after cyclophosphamide to reduce the 
tumour burden, but it should be noted that in the N . O . V . A .  leukaemia 
no tumour associated Ag has been demonstrated
In syngeneic mice given Gross virus induced leukaemia cells, the
addition of B .C.G. ,  l.P .,a fte r  cyclophosphamide tumour reduction, failed
1 . I (249)to prolong survival
After surgical reduction with incomplete excision of a rat polyoma
tumour, treatment with B . C . G .  increased the growth of remaining tumour with
(29
an associated increase in serum blocking activity , although if
associated with previous splenectomy and innoculation of unblocking
serum, B . C . G .  led to tumour regression.
In a tumour system (mammary adenocarcinoma implantation) in
which surgical excision of the growing tumour alone resulted in 100%
mortality from spontaneous métastasés, preoperative injection of B . C . G .
into the tumour or post operative therapy with B . C . G .  alone or B . C . G . -
tumour cell vaccine resulted in significantly prolonged survival and the
possibility of 'cure* since no residual tumour could be found at the
termination of the experiment in these animals
In patients with a variety of carcinomas the use of a B . C . G .
vaccination associated with alkylating agents appeared to show significant
survival increase at 6 months, 12 months and 24 months^^^^  ^. Unfortunately
this study contains more cases of breast cancer in the B . C . G .  treatment
groups and if  the tumour was known to be hormonally responsive then
hormones were given ; with the alkylating agent a 'leucocyte boosting
thymus extract' was given ; more members of the treatment groups received
alkylating agents ; objective responses were not recorded ; a portion of the
control group was retrospective and the dose of B . C. G.  in terms of living
organisms is unknown.
In 20 of 35 patients with carcinoma of head and neck, treated with
intradermal B . C . G . ,  isoniczid and methotrexate, there was a reduction
(9 ^ 9 )
in gross tumour volume lasting more than 60 days . There is, however, 
no conclusive evidence in this uncontrolled study that B . C . G .  and isoniazid 
added anything to the results obtained with methotrexate alone.
24 of 32 patients with Burkitt's disease, with remission after
cyclophosphamide therapy, were randomised into B . C . G .  and control 
(253)
groups . No protective or harmful effects of B . C . G .  immunotherapy 
in relation to relapse frequency or duration of remission were noted,
A highly significant difference has been reported between two 
groups of patients with acute lymphoblastic leukaemia, given B . C . G .  
by scarification, after tumour load reduction by systemic chemotherapy, 
sequential complementary systemic chemotherapy and intrathecal chemo­
therapy or irradiation* Patients without immunotherapy relapsed after an 
average remission of 66 days ; of the patients with immunotherapy, either 
B . C . G .  (Pasteur strain) or formaldehyde inactivated allogeneic cellspnly  
9 from 20 had relapsed at 130 days "254, 255, 256 , 257).
in acute myelogenous leukaemia, after remission induction by a 5
day course of daunamycin and cytosine arabinoside, tumour vaccine was
used in the maintenance of remission The patients were divided into
three groups ; the first receiving chemotherapy alone, the second receiving
the same chemotherapy plus Glaxo B . C . G .  (1 x 10  ^ live organisms delivered
9
by the heaf gun) and 1 x 10 irradiated leukaemia cells administered s.c.  and 
i . d . , the third receiving the same form of immunotherapy alone. The groups 
receiving immunotherapy alone, and immunotherapy plus chemotherapy did 
significantly better than the group receiving chemotherapy alone. Whether 
the B . C . G . ,  the irradiated cells or the combination were active in prolonging 
the remission is uncertain.
Remission after chemotherapy was significantly prolonged in 
acute myelocytic leukaemia, by B . C . G .  immunotherapy, using Tice
B . C . G .  in combination with methotrexate, compared with methotrexate
, (259)alone
B . C . G .  (Tice) induced significant improvement in survival in 
patients with surgically resected recurrent malignant melanoma compared, 
however,to surgery alone in retrospective control
Comparison of remission duration of malignant melanoma and cellular 
reactivity to both primary and recall antigens, between Glaxo B . C . G .  
given i . d . ,  and Pasteur Institute B . C . G . given by scarification, suggested 
that the Pasteur B . C . G .  by scarification was associated with an increased 
duration of remission and increased cellular reactivity . Unfortunately, 
the the validity of the comparison, the Pasteur dose was 1 x 10  ^ times greater 
than the Glaxo dose.
In a contrasting study in acute lymphatic leukaemia, using a different
strain of B . C . G .  (Research Foundation, Chicago), and without central nervous
system irradiation, the B . C . G .  treated group did poorly as compared to the 
(262)
other 2 groups . After remission induction with prednisolone and vincristine 
followed by methotrexate l . V . ,  26% of patients remained In remission on no 
therapy, 21% In remission on B . C . G .  therapy and 82% stayed in remission 
on maintenance therapy with prednisolone, vincristine and methotrexate.
I9l cases of acute lymphoblastic leukaemia treated with prednisolone/ 
vincristine , p-mercaptopurine, L-asparginase and high dose methotrexate 
and folinic acid rescue, were randomised into 3 groups ; no further treatment, 
twice weekly methotrexate, and B . C . G .  immunotherapy. Remission length
was greatest with methotrexate (52 weeks), intermediate with B . C . G . ,
(262)
(27 weeks), and worst with no treatment(l7 weeks) . in this trial 
the B . C . G .  used was Glaxo freeze dried and apart from causing 
lymphocytosis had no other conspicuous effect.
As an adjunct to chemotherapy, vincristine and D . T . I . C . ,  in 
patients with disseminated malignant melanoma, an immunisation protocol
■. . . 7 . .of the i .d.  innoculation of 2 x 10 Irradiated allogeneic melanoma cells, 
admixed with 50 pg of B . C . G . ,  resulted in a high number of objective 
regressions, associated with a transient fall in specific inhibitory effects 
of the patient's sera, on tumour directed cytoxic activity, of the patient's 
lymphocytes This is, however, a preliminary report without concurrent
controls.
In vitro studies showing that ascites tumours and lymphomas could be 
destroyed by the close approximation of macrophages stimulated by B . C . G . ,  
and the use of intra-lesional B . C . G .  to induce tumour regression of a 
carcinogen-induced transplantable hepato-card noma In Sewal 1-Wright guinea 
pigs stimulated interest in this method as an i m mu n o- the rap eut i c approach to 
cancer 226)^ The results obtained indicate that the growth of i .d .  
transplanted syngeneic tumours can be suppressed by intra-lesional B . C . G . ,  
not due to a direct cytotoxic effect of B . C . G .  on the tumour cells, but 
requiring the participation of the hosts Immune defences Optimal tumour
suppression requires B . C . G .  in close contact with the tumour cells.
Suppression of tumour growth in skin Is more effective than suppression 
of tumour g rowth in draining lymph nodes and this limitation of the effectiveness
of intra-lesional B . C . G .  is also apparent for intra-muscular tumour 
(220)implants . In contrast B . C . G . ,  Phipps strain, injected into 
established colon wall tumours of transplanted line -  16 hepato-carcinoma 
in guinea pigs, suppressed tumour growth if the tumour burden was limited 
(265)^ emphasising the possibility of immunotherapy in other than superficial 
sites.
In mice i .d .  injection of B . C . G .  into a methylcholanthrene induced
(228)
sarcoma prevented progressive growth of the sarcoma , the suppression 
being dependent on the number of organisms injected, 10  ^ colony forming
5units ( C . F . U . )  suppressing the growth of 5 x 10 tumour cells in 100% mice, 
whereas 10  ^ C . F . U .  suppressed the growth of 5 x 10  ^ mice in 50% mice.
The use of heat killed B . C . G . , or local inhibition of B . C . G . multiplication 
with isoniazid, did not interfere with local tumour suppression, but the 
elimination of immunologically committed small lymphocytes with mouse 
anti-thymocyte serum or cortisone acetate did abolish B . C . G .  suppression 
of tumour growth, in this model.
In a murine system employing three tumours, two of which were 
demonstrated to be of low antigenicity, tumour cells failed to grow when 
injected into syngeneic animals as a mixture with B . C . G .  This effect
was limited to tumour cells given at the same site as B . C . G .  In non-immune 
immunosuppressed mice the administration of B . C . G .  -  tumour mixture was 
associated with a temporary growth delay suggesting non immunological 
processes only partially suppress tumour growth.
A weakly immunogenic rat epithelioma of spontaneous origin, 
when implanted s.c.  with B . C . G .  showed inhibition of local tumour
development, decreased pulmonary métastasés and increased animal
vi
(234)
(235)survival . Similar results occurred when B. C. G.  was given w th
rapidly growing methycholanthrene- induced sarcoma cells in rats 
Rejection of the tumour -  B . C . G .  innoculation resulted in suppression of 
growth of a simultaneous challenge with cells of the same tumour at a 
contralateral s.c.  site.
O f seven patients treated with intra-lesional B . C . G . ,  four responded 
and two failed to respond. Assessment of the patients indicated that 
response was associated with an increased immune reactivity, as measured 
by various parameters, (lymphocyte stimulation by saline extract of melanoma 
or P . H. A.  inhibition of leukocyte migration to melanoma Ag, an increased 
T cell lymphocyte population as demonstrated by rosette formation with 
S. R. B. C. ,  in vitro lymphocytotoxicity against melanoma lines, or formation 
of anti-melanoma A b), and the presence of disease limited to the skin and lymph 
nodes (267).
Weekly intranodular injections of B . C . G .  (lyophilised Pasteur B . C . G . )  
into secondary cutaneous and subcutaneous melanoma deposits, until 
suppuration occurred, gave no indication of even a slight clinical or 
histological effect on the uninfected control nodules . Although no 
recurrence occurred in the 485 injected nodules only 2 of the 25 patients 
had no recurrent clinical tumour 2 years after completion of local treatment.
12 patients with advanced malignant melanoma received 0.1 ml 
B . C . G .  into multiple nodules on one occasion. Five of the 12 had 
temporary regression of the injected nodules and 2 of this group had
regression of uninjected nodules, and one of these was tumour free at
_ , ,, (269, 270) . . , ,3 years follow up . The regressions were associated with
sensitivity to D . N . C . B .  and increase in anti-tumour antibodies. The
patient with the complete sustained regression was the only one to have
only skin lesions and no lymph node or visceral disease.
An extension of these studies showed that of patients with skin
métastasés of malignant melanoma only^direct injection of the skin
métastasés with B . C . G .  resulted in 90% regression of injected lesions^
17% regression of uninjected lesions in immunocompetent patients
and approximately 25% of patients remained free of diseases for 1 -  6 years.
A  lower incidence of local control and no long term survivors were the results
in patients with subcutaneous or visceral métastasés.
B . C . G .  and prevention of tumour development.
Experimentally B . C . G .  has afforded protection against subsequent
challenge with a variety of tumours, by decreasing the tumour incidence,
delaying the development of tumours and increasing the survival of the hosts
(7, 162, 163, 272, 273)  ^ . ,,
. The effects were demonstrated in various small
animals, and against tumours administered by a variety of routes.
Favourable effects of B . C . G .  could also be demonstrated against
• u ■ 4. r • (273, 274 , 275) , _ ^ _  . . .oncogenesis by a variety of viruses , and B . C . G .  combined
with specific tumours, also afforded protection against subsequent tumour 
challenge <276, 236, 266, 232)_
In patients analysis of the subsequent development of neoplasia in
groups of individuals immunised with B . C . G .  gives contradictory results
often due to poor experimental design and statistical interpretation, and
failure to appreciate the varying reactions of B . C . G .  in different 
1 (154)populations
(277)The original analysis of data from Quebec found death from
leukaemia to be less common in B . C . G .  vaccinated individuals. Objections
(278)
to the method of statistical analysis lead to reappraisal of the results
and re-analysis suggested no relationship between B . C . G .  immunisation and
2r resL 
(280)
(279)the incidence of leukaemia . Simila ults and interpretation to these
latter figures were produced for Glasgow
(281 )A  study from Chicago suggested a significant decrease in 
leukaemia mortality In B . C . G .  immunised children. However, this study was 
retrospective and not randomised so that a definite demographic group was 
selected.
A  controlled randomised trial in Georgia and Alabama revealed no
difference in the subsequent development of leukaemia, lymphosarcoma or
(282)Hodgkin's disease in B . C . G .  immunised children . It should, however,
be noted that in this study the B . C . G .  immunisation programme gave no
(283)
increased protection against subsequent tuberculosis . This emphasises 
that the variability in the protection afforded by B . C . G .  against tuberculosis 
is like ly  to be reflected in a similar variability in effect I vity against tumours 
and cause similar problems in the interpretation of the results.
In a controlled trial in Puerto Rico, with an average follow up of 18.8 
years. It was found that B . C . G . immunised children had a very slightly 
decreased incidence of leukaemia, but an excess of lymphosarcoma and
M j  I • . (284)Hodgkin s disease
On the prevention of tumours induced by chemical carcinogens 
the effect of B . C . G .  has been much less conclusive than in other 
experimental models and since this is the aspect most related to the 
experimental work of this thesis the relevant experiments are given in 
detail.
B . C . G .  and chemical carcinogenesis.
3 -methyl cholanthrene dissolved in sesame oil was injected into
the right thigh muscle of Swiss II A . /  i .C.R.  mice. B . C . G .  infection
(1 mgm wet weight) prior to carcinogen injection did not consistently alter
the rate of tumour appearance or the final incidence. Infection with
B . C . G .  86 days following carcinogen injection caused a significant delay
in the appearance of tumours observed although the final cumulative
(8)incidence was similar to that seen in non-infected animals
Subcutaneous injection of 0 .5  mg M . C . A .  dissolved in 0.1 ml olive 
oil produced tumours in 80% of control S . W . M . / M . S .  control mice. Intra­
dermal injection of 0.1 ml B . C . G .  suspension containing 5 x 10^ viable cells 
2 weeks before M . C . A .  administration decreased tumour incidence 
significantly. B . C . G .  at the time the first mice were detected having 
palpable tumours was without effect in reducing tumour incidence 
However, it should be noted that the early injections were given i .d .  and 
the latter group i . p . ,  and that in the groups receiving %. p. injections the 
tumour incidence was slightly greater than the controls.
B . C . G . ,  1 mg living Bacilli given s . c . , on the same day as D . M . B . A .  
delayed appearance of mammary carcinomas in rats although the ultimate
incidence of tumours was similar. B . C . G .  given before, or within 
six weeks after, the D . M . B . A .  feeding had no effect on the rate of 
tumour production and B . C . G .  was given after the appearance of the 
first tumour, accelerated subsequent tumour growth In these
experiments B . C . G .  appeared to counteract the effects of D . M . B . A .  
induced depression of the spleen weight and the reduction of mononuclear 
spleen cells.
In C57BL/6 mice 1 ml B . C . G .  administered l .P.  (5 x 10  ^
organisms /  ml), given either 2 weeks before or 2 weeks after carcinogen 
administration, 500 pg 3 M . C . A . , provided significant temporary protection 
as demonstrated by a decreased rate of tumour appearance Methanol
extracted residue at a dose of 0 .5  mg provided relatively little  protection, 
but at a dose of 2 .5  mg provided significant temporary protection. In these 
experiments, however, with the amount of 3 M . C . A .  used, (500 pg I . M . ) ,  
almost all the mice developed tumours.
The hamster cheek pouch, using D . M . B . A .  as the carcinogen provides
a useful model since the tumours apparently develop in recognisable sequential
manner, the epidermoid carcinomas following the formation of hyperkeratosis
and dyskeratosis. Using this model, pouches from control hamsters painted
with D . M. B . A . ,had  uniform well developed epidermoid carcinomas when
examined histologically at 12 weeks. In contrast hamsters receiving B . C . G .
(1 mg B . C . G .  x 2 weekly for 14 weeks, starting week -  2 relative to painting
with D . M . B . A . )  had hyperkeratosis, some dyskeratosis and rare foci of
(288)epidermoid carcinoma , The changes at 12 weeks in the B . C . G .  group
resembled those in a group of controls that had been killed at 8 weeks, 
suggesting significant delay in the progression of carcinogenesis by B . C . G .
Charles River mice, painted once with 125 pg D . M . B . A .  (tumour 
initiation) followed by repeated applications of croton o il, 0 .6  mg twice 
weekly for 25 weeks (tumour promotion) received l . V .  1.0 mg B . C . G .  in 
0.1ml .  0 .08%  N aC l, 2 days after the D . M . B . A .  a p p l i c a t i o n . This 
reduced the rate of appearance and incidence of both benign and malignant 
skin tumours. In these experiments the animals treated with B . C . G .  which 
developed tumours had a larger spleen index than those animals which did 
not develop tumours. This may be due to the inability of the tumour bearing 
animals to destroy the tumours although they have the ability to recognise 
them. Thus, the reticulo-endothelial system is continually stimulated by the 
tumour antigens which it cannot eliminate. This failure of elimination may 
be due to the local immunosuppressive effect on the long continued croton oil 
applications or it may be that the enlarged spleen is producing antibody which, 
complexed to antigen, is blocking any cell mediated cytotoxic activity.
Persistent generalised B . C . G .  infection,followhg the intra-colonic
injection of B . C . G .  (6.7 x 10  ^ organisms) in rats, had no effect on the rate
of development or incidence of tumours induced by 1,2 -  dimethyIhydrazine
dihydrochloride ( D . M . H . )  given intragastrically for 5 weeks, but did increase
(290)the number of mucinous adenocarcinomas and métastasés
Part IV
PRELIMINARY EXPERIMENTS :
(I) TO CORRELATE THE CYTOLOGICAL CHANGES, THE MACROSCOPIC 
APPEARANCES A N D  THE HISTOPATHOLOGY.
(II) TO DEMONSTRATE THE IM M U N O G EN IC ITY  OF THE TUMOURS PRODUCED 
BY THIS METHOD.
(I) To ensure as far as possible that the cytological picture accurately reflected 
the progression of the neoplastic changes, preliminary experiments were carried 
out to determine which cytological features correlated with the stage of 
carcinogenesis as determined by the histological examination.
After the carcinogen implantation, the mice were followed by weekly 
cytological examination and immediately after the cytological examination each 
week, a batch of five mice was ki l led.  The macroscopic and histological 
features of the cervix were correlated with the cytological appearance of the 
exfoliated cells.
Pathological Anatomy
In those cases in which no tumour occurred the cervix either appeared 
little  different from normal apart from slight thickening or had a rough granular 
surface, but without any ulceration. Both of these appearances could be 
associated with intra-epitheliai malignant lesions, the rough granular surface 
being associated more commonly with the more severely dysplastic type of 
lesion. These appearances were found also associated with the formation of 
cords or strands of cells apparently invading into the underlying stroma or with 
definite micro-invasion.
The macroscopic appearances associated with the first cytological 
evidence of invasion were of thickening of the tissue around the cervical 
canal, giving a tubular, slightly swollen appearance. The epithelial 
surfaces appeared either granular or papillary and bulged into the lumen 
of the canal.
The majority of the invasive carcinomas were of the exophytic type 
and varied considerably in size. The lesions were located at the external 
os or in the endocervical canal. The smaller lesions were papillary and 
filled  the endocervical canal ; the larger tumours were often ulcerated and 
necrotic and invaded down into the vagina and up into the uterine horns.
Invasion into and around the rectum occurred and the ureters were 
obstructed by surrounding tumour masses.
Métastasés occurred In many cases, mainly to the lymph nodes of the 
lumbar region.
Histopathology
The initial response of the cervical tissue to the 20 M . C .  implantation 
was inflammatory with the formation of small mlcro-abscesses, containing 
polymorphonuclear leukocytes, in the epithelium. In the underlying connective 
tissue there was focal oedema also associated with collections of polymorpho­
nuclear leukocytes. After the initial inflammatory response, lasting about two 
weeks, the epithelial cells showed slight cytological variation with cell 
crowding, slight nuclear enlargement and hyperchromasia, but no increase in 
mitotic figures. As the lesions progressed, disordered proliferation of the 
basal cells gave rise to a compact very cellular stratum replacing the normal
single layer (Fig. 1 ) ,  Associated with this there were cellular atypias 
and some increased mitotic activity. The degree of atypia, however, 
was not marked. The orderly differentiation of the epithelium was also 
disturbed and a diffuse polymorphonuclear cell infiltrate was present 
throughout the epithelium.The epithelial lesions were usually diffuse, but 
occasionally isolated segments of sharply demarcated, increased basal 
activity could be demonstrated (Fig. II).  The cells in these segments 
contained enlarged, densely clustered nuclei, and were often sharply 
demarcated from the upper epithelial layers. These changes suggested 
the beginning of epithelial transformation with the growth of a new cell 
type, while the more diffuse proliferation associated with the polymorphonuclear 
infiltration suggested reaction to the irritant properties of the carcinogen.
With further progression more advanced atypical basal cell hyperplasia 
could be found with the basal cells showing enlargement and pleomorphlsm 
of the nuclei which were crowded together (Fig. 111). Mitoses were increased 
and in the enlarged nuclei, nucleoli were prominent. Above the atypical 
basal cell layers the epithelium was sharply demarcated and showed little  
abnormality.
Advanced atypical basal cell hyperplasia was often associated with two 
intro-epithelial lesions, (1) Dysplasia (2) In-situ carcinoma.
In moderate dysplasia above the atypical basal cells the number of 
nuclei decreased rapidly, but remained atypical throughout. Mitoses 
occurred only in the basal layers and leukocyte infiltration was found in the 
middle layers. There was an abnormally thickened and abnormally differentiated
FIG Basai cell hyperplasia : replacement of single basal cell layer 
by several strata of cells.
FIG . 11. Short segment of atypical hypeplastic basal cells suggestive of 
epithelial transformation to a new cell type.
FIG. More advanced atypical basal cell hyperplasia with pleomorphic 
cells and nuclei.
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FIG.  1V.  Moderate dysplasia with atypical nuclei through the full 
thickness of the epithelium.
basal ceil layer (Fig. IV ). On the surface there was pyknosis and 
parakeratosis. Occasionally associated with moderate dysplasia there 
were bulky epithelial outgrowths into the underlying stroma, but the 
basement membrane areas associated with these remained intact.
In severe dysplasia the architecture of the epithelium was disordered 
in the basal layers, and this was associated with marked nuclear pleomorphism 
and atypia (Fig. V ). The cells however, in all layers remained clearly 
defined. M itotic activity was greatly increased but was limited to the 
basal layers. In all cases some degree of differentiation took place in the 
upper layers. Severe dysplasia was often associated with bulky downgrowths 
of epithelium into the connective tissue stroma or with slender pegs of 
epithelium separated by elongated stromal papillae. In some areas foci of 
nuclear clumping could be found.
in carcinoma in situ the normal stratified structure of the epithelium was 
no longer recognisable due to the great increase in atypical cells and nuclei 
(Fig, V I) ,  through the entire thickness of the epithelium. Cell borders were 
difficult to recognise. The epithelial structure was severely disordered 
because of the complete loss of nuclear polarity and in many cases mitoses 
were present right up to the surface. The cells forming the carcinoma ïn-sîtu 
were often spindle-shaped undifferentiated cells although others had larger 
nuclei and more variations in nuclear form. Bulky outgrowths of the epithelium 
into the underlying stroma often occurred, and in these outgrowths the cells 
often showed numerous mitoses, but the basal cell layer always remained well 
defined and bordered the intervening stromal papillae.
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PIG. V.  Severe dysplasia with disordered architecture associated with 
marked nuclear pleomorphism and atypia.
A
FIG.  VI .  Carcinoma in-situ with greatly increased numbers of atypical 
cells and nuclei resulting in loss of normal stratified structure
Early invasive growth was always found in association with an atypical 
epithelium, either from severely dysplastic epithelium or from in-situ 
carcinoma (Fig. V II). The majority of the invasive lesions were associated 
with severe dysplasia and the minority with ïn-situ carcinoma. Only one 
case of invasive carcinoma was found associated with a relatively mild 
degree of dysplasia.
In some cases one change suggestive of invasion was the appearance 
of a dense lymphoid and plasma cell Infiltrate in the stroma beneath the 
epithelium (Fig. Vl l l ) .  The focal inflammatory response was so dense that 
the border between the epithelium and stroma could not be identified.
Pointed and forked invasive pegs often grew down from either dysplastic 
epithelium or in-situ carcinoma (Fig. IX).  The pegs often showed more 
differentiation than the epithelium from which they were apparently arising, 
and they were not surrounded by any recognisable basal membrane layer.
Thin cords of atypical basal cells could also be found penetrating 
deeply into the stroma often eliciting little  evidence of any tissue response 
(Fig. X ).
The progression of the micro-invasive lesions took the form of advancing 
cords of epithelial cells into the stroma with numerous branching processes 
(Fig. XI ) .  In the immediate neighbourhood of the Invasive lesion there was 
stromal oedema and a lymphoid cell and macrophage In filtrate.
In other lesions the Invasion was on a broad front over a segment of 
epithelium with relatively little  evidence of stromal changes or an inflammatory 
response, and similar type of invasion appeared to arise from nodular epithelial 
downgrowths (Fig. Xl l ) .
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FIG.  VI I .  Early invasion from a dysplastic epithelium.
FIG.  Vl l l .  Early invasion with associated lymphoid and plasma cell 
infiltrate in the underlying stroma.
IFIG.  ' IX. Invasive pegs growing down from dysplastic epithelium.
FIG.  X .  Cords of atypical basal ceils penetrating into the stroma with little 
tissue response.
The progression of the invasion ultimately gave rise to the tumours 
of cervix, the majority of which were well-differentiated squamous 
carcinomas (Fig. Xl l l ) ,  but a few moderately well-differentiated carcinomas 
were also produced. These tumours ultimately invaded locally to the 
bladder,around the ureters and into the wall of the rectum (Fig. XIV) .
Métastasés to local lymph nodes also occurred.
When the invasive lesion was well advanced the lymphoid Infiltrate 
was limited to the periphery and often was markedly reduced. At this stage 
it consisted mainly of small lymphocytes and scattered plasma cells.
Cytopathology
The early response of the cervical epithelium to the implantation of 
20 M . C .  was reflected In the vaginal smear by large numbers of polymorphonuclear 
leukocytes, many clumped around necrotic squamous cells, correlating with 
the tissue sections showing focal polymorphonuclear infiltration with the 
formation of small micro-abscesses in the epithelium. This inflammatory 
exudate continued for two weeks and then subsided.
After the initial inflammatory response the exfoliated cells were 
characterised by increasing numbers of basal and parabasal cells in which 
there were cytoplasmic alterations ( Fig. XV) .  These consisted of increased 
cytoplasmic basophilia, some cells having fine granularity, others being 
very coarse-grained. This cytoiogical picture and cell type corresponded with the 
early dysplastic changes in the cervical epithelium.
As the lesions advanced, plump hyper chromatic basal cells made their 
appearance in large numbers (Fig. XVI ) .  These cells corresponded to the 
cervical changes of severe dysplasia, in which there was disordered growth
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FIG.  XI . Epithelial cells invading into the stroma with branching processes ;
there is associated stromal oedema and a lymphoid infiltrate.
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FIG . Xl l .  Invasion arising from a nodular epithelial downgrowth.
FIG.  XI I I .  Advanced squamous carcinoma of cervix.
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F I G . XIV.  Squamous carcinoma invading into the wall of the rectum.
and increased mitotic activity of the basal and parabasal regions and the 
presence of plump nucleated parabasal cells near the surface. The surface 
was formed by a thin layer of keratin. Later many of the exfoliated cells 
showed nuclear evidence of malignant transformation similar to that of the 
cells exfoliated in in-situ carcinoma, it was these cells, together with 
those found associated with in-situ carcinoma, that were regarded as the 
first malignant cells (Fig. XVI I ) .
in the animals showing the lesion consistent with carcinoma in-situ 
the exfoliated cells showed marked variation in shape and size with large 
nuclei showing a definite increase in the nucleo-cytoplasmic'ratio (Fig. XVI I I ) .  
Multinucleate cells were also present Fig. XIX) .  The chromatin pattern was 
coarse and the nuclei hyperchromatîc. The cytoplasmic changes were similar 
to those found in severe dysplasia. Nucleoli were not prominent. This 
cytoiogical picture corresponded with sections showing very marked 
proliferation of basal and parabasal cells with thickening of the epithelium, 
but with the basal membrane remaining intact. The papillomatous projections 
of cells were larger and more cellular than in severe dysplasia, there was 
marked cell crowding and the nucleated malignant cells were present at the 
surface with no layer of keratin. The nuclei of the cells were enlarged and 
hyperchromatic and there were greatly increased numbers of mitotic figures 
at all levels.
At the stage of early invasive carcinoma the smears were very similar 
to those found in animals with in-situ carcinoma, except that neoplastic cells 
were found in larger numbers and included more atypical squamous cells from
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FIG . X V . Exfoliated basal and parabasal cells corresponding to early 
dysplasia.
F IG . X V I. Plump hyperchromatic basal cells corresponding to more severe 
dysplasia.
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FIG . X V II. Cells with large nuclei, increased nucleo-cytoplasmic ratio and
hyperchromatic nuclei : these cells were regarded as the first malignant
cells.
F IG . X V III. Exfoliated cells corresponding with in-situ carcinoma.
iF IG . X IX . Multinucleated cell from in-situ carcinoma.
F IG . X X . Exfoliated cells corresponding to early invasive carcinoma with 
polymorphonuclear leukocytes and red blood cells.
the surface (Fig. X IX ). Nucleoli were more prominent. A t this stage 
too, polymorphonuclear leukocytes returned in large numbers and the 
smears contained red blood cells, but the essential difference between the 
invasive and the non-invasive lesion was quantitative. An important 
feature of the invasive lesion was that during the dysplastic and in-situ 
stage, the exfoliated cells remained cyclic, but when invasion occurred 
the cyclic pattern was distorted and basal and parabasal cells predominated 
with fewer kerotinised and luteinised cells being exfoliated.
This correlation enabled us to be certain that the first cytologically 
malignant cells found were associated with definable histological lesions 
and that, with the relatively narrow range of variations in this model, it 
would be possible to assess what different histological stages had been reached, 
for the control of therapy.
One important point is that it was not possible to determine cytol ogicall y 
the exact time of breaching of the basement membrane, so that the term 
'earliest invasion demonstrable' in this experiment means the earliest time we 
could be certain invasion was taking place rather than being synonomous with 
breaching of the basement membrane or 'micro-invasion'. Even within the 
relatively narrow range of variations in this experimental model we found it 
impossible to reliably detect micro-invasion cytoiogically, although this 
would have been the ideal,
A  second point is that it was demonstrated that invasive carcinoma 
arose almost equally, in this model, from severe dysplasia and in-situ carcinoma.
(Il) Preliminary experiments were also carried out to demonstrate that 
the tumours produced were immunogenic.
Tumours were induced in the cervix of two groups of four inbred 
Swiss virgin female mice, aged six to nine weeks, using the techniques 
previously described. One group was treated as in the ST experiment with 
the carcinogen remaining in position, the other as in the LT experiment 
in which the carcinogen was removed. Tissue from each tumour was used 
to immunise four separate groups of 12 syngeneic virgin female mice by 
subcutaneous (s .c .) innoculation of the tumour fragments by a trocar. A  
similar number of uninnoculated animals served as controls. In the experimental 
group the growing tumour was excised after eight to ten days, and at the time 
of excision sham operations were performed in the controls.
Ten days after the removal of the tumour and the sham operation both 
groups of animals were irradiated and twenty-four hours later each group was 
challenged by the s.c. innoculation of I x 10  ^ tumour cells suspended in 0.1 ml 
Eagles tissue culture medium, prepared by enzymatic (trypsin) digestion of 
tumour of the second transplant generation.
The animals were examined weekly for evidence of tumour outgrowth (the 
latent period) and at twenty weeks the diameter of the tumour measured.
In the group treated as the ST group, with the carcinogen remaining in 
position, of the four tumours tested three showed evidence of immunogenicity 
and in each of the cases all the animals showed resistence to tumour growth, in 
terms of latency and tumour growth compared to the controls.
The fourth tumour showed s trong immunogenicity and all twelve 
experimental animals showed complete resistence to growth, while II of 
the 12 control animals developed tumours.
In the group treated as in the LT experiment with the carcinogen removed 
on the detection of the first malignant cells, with all four of the tumours tested 
there was more resistence to tumour growth in the experimental group than in 
the controls, but their differences were much less marked than in the ST group.
In both experimental and control LT groups the latent period was longer than in 
the ST groups, and the ultimate size of the tumours smaller, suggesting that in 
comparison to the ST group the tumours were less immunogenic and slower growing.
PART V  RESULTS
A) The S.T . Group of experiments.
The results of the S.T.  Group 1 experiments in which the carcinogen 
remained in position throughout and in which A. L . S.  and N . H . S ,  were 
started, and the injection of B . C . G .  or saline given, on day -14 relative 
to the time of carcinogen implantation, are given in Table 1 and Figure XX l .
These show that at the time of termination of the experiment there was 
a marked difference between the number of tumours developing in the mice 
receiving A . L . S . ,  15 out of 20 mice, (75%), and the mice receiving B . C . G . ,
8 out of 20 mice, (40% ). However, when the number of mice with micro 
invasive carcinoma is included it is seen that the difference in the number of 
mice developing invasive carcinomas is much less marked ; In the group 
receiving A . L . S .  16 out of 20 mice (80%) and in the B . C . G .  group 13 out 
of 20 mice (65% ), have developed invasive lesions. Severe dysplasia and / or 
carcinoma-in-situ, both epithelial forms from which invasive lesions can arise, 
are found in 4 out of 20 mice (20%) in the A . L . S .  group and 5 out of 20 mice 
(25%) in the B . C . G .  group, so that at the termination of this experiment, in 
the A . L . S .  group, 20 out of 20 mice (100%) had either developed invasive 
malignancy or had epithelium which retained the potential to develop invasive 
carcinoma, while in the B . C . G .  group 18 out of 20 mice (90%) hod similar 
changes. In the control groups receiving N . H . S .  or saline the figures were 
similar, suggesting that while the carcinogen remains in position, in 
experiments of short duration such as this, the effects of A . L . S .  and B . C . G .  
are merely to increase or delay the rate of development of invosvie carcinoma. 
This is emphasised by the finding that at the termination of the experiment 
there was no significant difference in the number of mice with normal epithelium, 
in either the experimental or control groups.
TABLE t : S.T. GROUP I.
Tumours ultimately developed in :
In the control group, receiving N . H . S , ,  12 out of 20 mice : 60%
In the experimental group receiving A . L . S . ,  15 out of 20 mice : 75%
In the experimental group receiving B . C . G . ,  8 out of 20 mice : 40%
In the group receiving saline, II out of 20 mice : 55%
Micro-invasive carcinoma was detected at post-mortem in :
In the control group receiving N . H . S . ,  3 out of 20 mice : l5%
In the experimental group receiving A . L . S . ,  I mouse out of 20: 5%
In the experimental group receiving B . C . G . ,  5 mice out of 20 : 25%
In the group of controls receiving saline, 3 mice out of 20 : 15%
Severe dysplasia and/or carcinoma in-situ was found at the post-mortem in :
In the control group receiving N . H . S . ,  4 out of 20 mice : 20%
In the experimental group receiving A . L . S . ,  4 out of 20 mice : 20%
In the experimental group receiving B . C . G . ,  5 out of 20 mice : 25%
In the control group receiving saline, 5 out of 20 mice : 25%
A normal cervix or a cervix showing mild dysplasia was found at post-mortem in 
In the control group receiving N . H . S . ,  I out of 20 mice : 5%
In the experimental group receiving A . L . S . , 0 out of 20 mice : 0%
In the experimental group receiving B . C . G . ,  2 out of 20 mice : 10%
In the control group receiving saline, 1 out of 20 mice : 5%
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F I G . X X I .  S.T .Group I : Carcinogen remaining in position throughout experiment
A. L . S .  and N . H . S .  : Started day -  14 relative to
carcinogen implantation,
B .C . G.  and saline : Given day -  14 relative to
carcinogen implantation.
In S.T.  Group II where the A . L . S .  and N . H . S .  were started on 
the day of carcinogen implantation and in which B . C . G .  or saline were 
given at this time the results are given in Table II and Figure XX I I ,
The results are very similar to those in S.T. Group I the only 
difference being that relatively more of the B . C . G .  sub-group had either 
severe dysplasia or in-situ carcinoma at the termination of the experiment,
44%ysuggesting more marked delay in the progression to invasive carcinoma, 
but the numbers with normal epithelium at the termination of the experiment, 
in both experimental and control groups, were the same.
When A . L . S .  or B . C. G.  was delayed until the first malignant cells 
were detected cytologically, S.T. Group III i . e .  when the epithelium showed 
either severe dysplasia or in-situ carcinoma, the results in the different 
sub-groups and controls were similar to each other, (Table III and Figure XXI I I )  
and were also similar to the other experimental groups S.T.  I and S.T.  I I .
In S.T.  Group IV  where the A . L . S .  and N . H . S .  were started at the 
first cytoiogical evidence of invasion and in which B . C . G .  was started at 
the same tim e, the most significant finding was that 95% of the mice 
receiving A . L . S .  had either tumours or early invasive lesions, compared with 
78% of the mice receiving N . H . S . ,  49% of the mice receiving B . C . G .  and 
78% of the mice receiving saline. The other significant finding was that
B . C . G .  seemed capable of causing reversion of the lesion to a pre-invasive 
state, (39% of the mice), but not to a normal epithelium, in higher numbers 
than in the control groups. Table IV  and Figure XXIV.
TABLE H : S.T. GROUP H
Tumours ultimately developed in ;
In the control group receiving N . H . S . ,  13 out of 24 mice : 54.16%
In the experimental group receiving A . L . S . ,  12 out of 19 mice : 63.15%
In the experimental group receiving B . C . G . ,  4 out of 18 mice : 22.22%
In the control group receiving saline, 8 out of 15 mice : 53.33%
Micro-invasive carcinoma was detected at post-mortem in:
In the control group receiving N . H . S . ,  4 out of 24 mice : 16.66%
In the experimental group receiving A . L . S . , I out of 19 mice : 5 .26%
In the experimental group receiving B . C . G . ,  4 out of 18 mice : 22.22%
In the control group receiving saline, 3 out of 15 mice : 20%
Severe dysplasia and/or carcinoma in-situ was found at post-mortem in :
In the control group receiving N . H . S . , 7 out of 24 mice : 29.16%
In the experimental group receiving A . L . S . ,  4 out of 19 mice : 21.05%
in the experimental group receiving B . C . G . ,  8 out of 18 mice : 44.44%
In the control group receiving saline, 3 out of 15 mice : 20%
A normal cervix or a cervix showing mild dysplasia was found at post-mortem in :
In the control group receiving N . H . S . ,  0 out of 24 mice : 0%
in the experimental group receiving A . L . S . ,  2 out of 19 mice : 10.52%
in the experimental group receiving B . C . G . ,  2 out of 18 mice : II .11%
In the control group receiving saline, I out of 15 mice : 6.66%
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FIG . X X I I . S . T . Group I! : Carcinogen remaining in position throughout experiment.
A . L . S .  and N . H . S .  : Started on day of carcinogen
implantation.
B . C . G .  and saline Given on day of carcinogen 
implantation.
TABLE 111 : S.T. GROUP III
Tumours ultimately developed in :
In the control group receiving N . H . S . ,  8 out of 18 mice : 42.10%
In the experimental group receiving A . L . S . ,  13 out of 19 mice: 68.42%
In the experimental group receiving B . C . G . ,  5 out of 13 mice : 38.46%
In the control group receiving saline, 8 out of 15 mice : 53.33%
Micro-invasive carcinoma was detected at post-mortem in :
In the control group receiving N . H . S . ,  4 out of 19 mice : 21.05%
In the experimental group receiving A . L . S . , 2 out of 19 mice : 10.52%
In the experimental group receiving B . C . G . ,  3 out of 13 mice : 23.07%
In the control group receiving saline, 4 out of 15 mice : 26.66%
Severe dysplasia anc|/or carcinoma in-situ was found at post-mortem in :
In the control group receiving N . H . S . ,  5 out of 19 mice : 26.31%
In the experimental group receiving A . L . S . ,  4 out of 19 mice : 21.05%
In the group receiving B . C . G . ,  3 out of 13 mice : 23.07%
In the control group receiving saline, 2 out of 15 mice : 13.33%
A normal cervix or a cervix showing mild dysplasia was found at post-mortem in : 
In the control group receiving N . H . S . ,  2 out of 19 mice ; 10.52%
In the experimental group receiving A . L . S . ,  0 out of 19 mice : 0%
In the experimental group receiving B . C . G . ,  2 out of 13 mice : 15.38%
In the control group receiving saline, 1 out of 15 mice : 6.66%
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F I G . X X I I I . S.T.  Group III : Carcinogen remaining in position throughout experiment,
A . L . S .  and N . H . S .  : Started at time of detection of
first malignant cells by cytology.
B . C . G . and saline Given on first detection of 
malignant cells by cytology.
TABLE IV . : S .T . GROUP IV .
Tumours ultimately developed in :
In the control group receiving N . H . S . ,  8 out of 18 mice : 44.44%
In the experimental group receiving A . L . S . , 18 out of 22 mice : 81.81%
In the experimental group receiving B . C . G . ,  6 out of 18 mice : 33.33%
In the control group receiving saline, 9 out of 16 mice : 56.25%
Micro-invasive carcinoma was detected at post-mortem in :
In the control group receiving N . H . S . ,  6 out of 18 mice : 33.33%
In the experimental group receiving A . L . S . , 3 out of 22 mice : 13.63%
In the experimental group receiving B . C . G . ,  3 out of 18 mice : 16.66%
In the control group receiving saline, 5 out of 16 mice : 31.25%
Severe dysplasia and/or carcinoma in-situ was found at post-mortem in :
In the control group receiving N . H . S . ,  3 out of 18 mice : 16.66%
In the experimental group receiving A . L . S . , 1 out of 22 mice : 4 .54%
in the experimental group receiving B . C . G . , 7 out of 18 mice : 38.88%
In the control group receiving saline, 1 out of 16 mice : 6.25%
A normal cervix or a cervix showing mild dysplasia was found at post-mortem in :
In the control group receiving N . H . S . ,  1 out of 18 mice : 5.55%
In the experimental group receiving A . L . S . , 0 out of 22 mice : 0%
In the experimental group receiving B . C . G . ,  2 out of 18 mice : 11.11%
In the control group receiving saline, 1 out of 16 mice : 6.25%
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FIG.  X X I V .  S.T.  Group IV : Carcinogen remaining in position throughout experiment.
A . L .S .  and N . H . S .  : Started at first evidence of invasion
detected by cytology.
B . C . G .  and saline Given at first evidence of invasion 
detected by cytology.
B) The L.T.  Group of experiment.
The results of the experiments In which the carcinogen was removed when 
the first malignant cells were detected cytologically, the L.T.  experiments, 
are given in Tables V  to V III and Figures XX V  to XXVl l l .
In the L.T.  group in which A . L . S .  and N . H . S .  were started on the day 
of implantation of the carcinogen and the injection of B . C . G .  or saline given 
at that time there was a marked difference In the number of mice developing 
tumours between the group receiving A . L . S .  12 out of 18 mice, 66% , and the 
controls receiving N . H . S . ,  8 out of 16 mice, 50%. O f the experimental group 
receiving B . C. G.  6 out of 21 mice, 2 8 . 5%,  developed tumours whereas in the 
control group receiving saline 8 out of 18 mice, 44 .5 % , developed tumours 
(Table V and Fig. X X V ). From these It can also be seen that the percentage of 
mice, receiving A . L . S .  developing tumours was also markedly increased over the 
group receiving B . C . G .
When the numbers of mice developing micro-invasive carcinoma is included 
it can be seen that in contrast to the S.T.  experiments the difference in the 
numbers of mice developing invasive lesions between the group receiving A . L . S .
15 out of 18 mice, 92%, and the group receiving B . C . G .  7 out of 21 mice, 33%  
in appreciable. This contrasting effect of A . L . S .  and B . C . G . ,  when the 
carcinogen has been removed is emphasised when the number of mice with tumours, 
early Invasive carcinoma, or severe dysplasia and carcinoma in-situ,is demonstrated 
at the termination of the experiment, when it can be seen that 17 out of 18 mice, 
94 .5% , receiving A . L . S .  had either developed, or retained the potential to develop,
invasive carcinoma whereas in the group receiving B . C . G .  lO out of 21 mice, 4 7 .5 % , 
and in the control groups 12 out of 16, 75% , and 14 out of 18 mice, 7 7 .5% , were 
in this category.
TABLE V : L .T . GROUP 1
Tumours ultimately developed in :
In the control group receiving N . H . S . ,  8 out of 16 mice : 50%
In the experimental group receiving A . L . S . ,  12 out of 18 mice : 66.66%
In the experimental group receiving B . C . G . ,  6 out of 21 mice : 28.57%
In the control group receiving saline, 8 out of 18 mice : 44.44%
Micro-invasive carcinoma was detected at post-mortem in :
In the control group receiving N . H . S . ,  2 out of 16 mice : 12,5%
In the experimental group receiving A . L . S . , 3 out of 18 mice : 16.66%
In the experimental group receiving B . C . G . ,  1 out of 21 mice : 4 .76%
In the control group receiving saline, 2 out of 18 mice : 11.11%
Severe dysplasia anc|/or carcinoma in-situ was found at post-mortem in :
In the control group receiving N . H . S . ,  2 out of 16 mice : 12.5%
In the experimental group receiving A . L . S . , 2 out of 18 mice : 11.11%
In the experimental group receiving B . C . G . ,  3 out of 21 mice : 14.28%
In the control group receiving saline, 4 out of 18 mice : 22.22%
A normal cervix or a cervix showing mild dysplasia was found at post-mortem in : 
In the control group receiving N . H . S . ,  4 out of 16 mice : 25%
In the experimental group receiving A . L . S . ,  1 out of 18 mice : 5.55%
In the experimental group receiving B . C . G . ,  11 out of 21 mice : 52.3%
In the control group receiving saline, 4 out of 18 mice : 22.22%
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FIG.  X X V . L.T.  Group I : Carcinogen removed when first malignant cells detected
by exfoliative cytology.
A . L . S .  and N . H . S .  : Started on day of implantation
of carcinogen.
B . C . G .  and saline : G iven on day of Implantation of
carcinogen.
Further emphasis for the contrasting effects of A . L . S .  and B . C . G .  when 
the carcinogen has been removed is found in the figures for the number of 
cervices which had returned to normal at the end of the experiment, in the
A. L . S .  group only 1 out of 18 mice, 5 . 5%,  had an apparently normal cervix 
whereas in the B . C . G .  group 11 out of 21 mice, 52%, had reverted to normal.
In the control groups 4 out of 16 mice, 25% , and 4 out of 18 mice, 22% , had 
returned to normal from a potentially invasive epithelium.
In L.T.  group 2 , in which A . L . S .  and N . H . S .  were started on the day 
of removal of the card nogen and B . C . G .  and saline injections were given that 
day the figures for all the groups were similar to those of the L.T.  group I ,  and 
no effect could be demonstrated, of the delay in giving A. L . S.  or B . C . G .
Cable VI and Fig. XXVI ) .
These experiments emphasise that when the carcinogen is removed A . L . S .  
or B . C . G .  have a marked effect on the progression or regression of potentially 
invasive epithelium. In this situation A . L . S .  prevents the reversion of the 
epithelium to normal and promotes the development of invasive carcinoma. In 
contrast B . C . G .  increases the number of cervices reverting to normal in 
comparison to the controls and A . L . S .  groups, and also decreases the number of 
carcinomas forming.
In L.T.  groups 3 and4 an attempt was made to further reduce the influence 
of the carcinogen by waiting three months after removal of the carcinogen and 
sub-dividing the mice into two experimental groups, L.T. group 3 with cytological 
evidence of In-situ malignancy, and L.T.  group 4 with cytological evidence of 
early invasive carcinoma but with no visible or palpable tumour.
TABLE VI : L .T . GROUP 2
Tumours ultimately developed în :
In the control group receiving N . H . S . ,  9 out of 21 mice : 42.85%
In the experimental group receiving A . L . S . , 12 out of 16 mice ; 75%
In the experimental group receiving B . C . G . ,  5 out of 18 mice : 27.77%
In the control group receiving saline, 10 out of 20 mice : 50%
Micro-invasive carcinoma was detected at post-mortem in ;
In the control group receiving N . H . S . ,  4 out of 21 mice : 19.04%
In the experimental group receiving A . L . S . , 1 out of 16 mice : 6 .25%
In the experimental group receiving B . C . G . ,  3 out of 18 mice : 16.66%
In the control group receiving saline, 2 out of 20 mice : 10%
Severe dysplasia ancj/or carcinoma in-situ was found at post-mortem in ;
In the control group receiving N . H . S . ,  4 out of 21 mice : 19.04%
In the experimental group receiving A . L . S . , 1 out of 16 mice ; 6 .25 %
In the experimental group receiving B . C . G . ,  2 out of 18 mice : 11,11%
In the control group receiving saline, 5 out of 20 mice : 25%
A normal cervix or a cervix showing mild dysplasia was found at post mortem in : 
In the control group receiving N . H . S . ,  4 out of 21 mice : 19.04%
In the experimental group receiving A . L . S . , 2 out of 16 mice : 12.5%
In the experimental group receiving B . C . G . ,  8 out of 18 mice : 44.44%
In the control group receiving saline, 3 out of 20 mice : 15%
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  L J .  Group 2 : Carcinogen removed when first malignant cells detected
by exfoliative cytology.
A . L . S . /  and N . H . S .  : Started on day of removal of
carcinogen.
B . C . G .  and saline : Given on day of removal of
carcinogen.
In L.T.  group 3 the results (Table V ll and Fig. X X V I1) were essentially 
the same as In L.T.  groups I and 2 , and demonstrated a marked effect of 
A. L . S .  by the increased incidence of tumours and in the maintenance of an 
in-situ malignancy and a corresponding failure of the reversal of the epithelium 
to normal with none of the mice receiving A. L . S .  having a normal epithelium 
at the termination of the experiment.
B . C . G .  had a marked contrasting effect with only 3 out of 16 mice,
18.7 % , forming tumours and 10 out of 16 mice, 62.5% , reverting to a normal 
epithelium while In the control groups receiving N . H . S . ,  3 out of 20 mice,
15%, or saline, 4 out of 19 mice, 21%, reverted to normal.
In L.T.  group 4 the effect of immune stimulation and im mu no-suppression 
on early invasive carcinoma was demonstrated (Table VI I I  and Fig. XXVl l l ) .
As might have been expected the incidence of tumours developing in the controls 
was higher than in the other L.T.  groups being 60% and 69.5%  in the N . H . S .  
and saline control groups respectively.
In the experimental group receiving A. L . S .  13 out of 15 mice, 86 .6% , 
ultimately developed tumours and 1 out of 15 mice, 6,6%,  had a micro-invasive 
carcinoma. One mouse had an In-situ preinvasive lesion and none of the mice 
had a normal cervix at the termination of the experiment.
O f the group receiving B . C . G .  2 out of 15 mice developed tumours and 
3 out of 15 mice had micro-invasive carcinoma at the termination of the experiment 
giving an incidence of 5 out of 15 mice, 33 .3% , with definite invasive lesions. 
Three out of 15 mice, 20% , had either severe dysplasia or in-situ carcinoma and 
7 out of 15 mice, 4 6 .5 % , had mild dysplasia or normal epithelium, suggesting that 
with early invasive lesions B . C . G .  could be effective in preventing tumour 
development and could cause reversal of the malignant epithelium to normal. In 
this group none of the control mice reverted to normal.
TABLE V ll : L .T . GROUP 3
Tumours ultimately developed in :
In the control group receiving N . H . S . ,  9 out of 20 mice : 45%
In the experimental group receiving A . L . S . , 13 out of 18 mice : 72.22%
in the experimental group receiving B . C . G . ,  3 out of 16 mice : 18.75%
In the control group receiving saline, 8 out of 19 mice : 42.10%
Micro-invasive carcinoma was detected at post-mortem in :
In the control group receiving N . H . S . ,  3 out of 20 mice : 15%
In the experimental group receiving A . L . S . , 2 out of 18 mice : 11.11%
In the experimental group receiving B . C . G . ,  1 out of 16 mice : 6 .25%
In the control group receiving saline, 3 out of 19 mice : 15.78%
Severe dysplasia ancj/or carcinoma in-situ was found at post-mortem in :
In the control group receiving N . H . S . ,  5 out of 20 mice : 25%
In the experimental group receiving A . L . S * ,  3 out of 18 mice : 16.66%
In the experimental group receiving B . C . G . ,  2 out of 16 mice : 12,5%
In the control group receiving saline, 4 out of 19 mice : 21.05%
A  normal cervix showing mild dysplasia was found in:
In the control group receiving N . H . S . ,  3 out of 20 mice : 15%
In the experimental group receiving A . L . S . , 0 out of 18 mice : 0%
In the experimental group receiving B . C . G . ,  10 out of 16 mice : 62 .5%
In the control group receiving saline, 4 out of 19 mice : 21.05%
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FIG . X X V I I . L.T.  Group 3 : Carcinogen removed when first malignant cells detected.
3 months after removal of carcinogen mice with evidence 
of in-situ carcinoma anc^or severe dysplasia, but with no 
evidence of invasion grouped into this experiment.
A . L . S .  and N . H . S .  : Started 3 months after removal of
carcinogen.
B . C . G .  and saline Given 3 months after removal of
carcinogen.
TABLE V III : L .T . GROUP 4
Tumours ultimately developed in :
In the control group receiving N . H . S . ,  9 out of l5 mice ; 60%
In the experimental group receiving A . L . S . , 13 out of 15 mice : 86.66%
In the experimental group receiving B . C . G . ,  2 out of 15 mice : 13.33%
In the control group receiving saline, 10 out of 16 mice : 62 . 5%
Micro-invasive carcinoma was detected at post-mortem in :
In the control group receiving N . H . S . ,  4 out of l5 mice : 26.66%
In the experimental group receiving A . L . S . , I out of 15 mice : 6 .66%
In the experimental group receiving B . C . G . ,  3 out of 15 mice : 20%
In the control group receiving saline, 5 out of 16 mice : 31.25%
Severe dysplasia an4/or carcinoma in-situ was found at post-mortem in :
In the control group receiving N . H . S . ,  2 out of 15 mice : 13.33%
In the experimental group receiving A . L . S . ,  I out of 15 mice : 16.66%
In the experimental group receiving B . C . G . ,  3 out of 15 mice : 20%
In the control group receiving saline, I out of 16 mice : 6 .25%
A normal cervix or a cervix showing mild dysplasia was found at post-mortem in :
In the control group receiving N . H . S . ,  0 out of 15 mice : 0%
In the experimental group receiving A . L . S . ,  0 out of 15 mice : 0%
In the experimental group receiving B.C. G . ,  7 out of 15 mice : 46 .66%
In the control group receiving saline, 0 out of 16 mice :0%
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F I G . XXVl l l .  L.T.  Group 4 : Carcinogen removed when first malignant cells detected.
3 months after removal of carcinogen mice with cytological 
evidence of invasion, but no palpable tumour, grouped întc 
this experiment.
A . L . S .  and N . H . S .  : Started 3 months after removal of
carcinogen.
B . C . G .  and saline Given 3 months after removal of
carcinogen.
c ) The length of time from carcinogen implantation to the detection of 
the first malignant cells.
Details of the results of the experiment designed to determine the effect 
of A . L . S .  and B . C . G .  on the time from the implantation of the carcinogen 
to the detection of the first cytologically malignant cells are shown in Table IX .
The animals were from the S.T.  I, S.T.  11, and L.T.  I and L.T^ 2 experiments.
O f the groups receiving N . H . S . ,  55 animals produced malignant cells 
and were available for statistical analysis. This showed a mean time to the 
production of malignant cells of 7.18 weeks with a standard deviation (S.D. )  
of 2 . 0 .
In the A . L . S .  group the 54 animals included for analysis had a mean time 
to the production of malignant cells of 7.18 weeks (S.D.  2 .0) .
In the group receiving B . C . G .  the 44 animals included had a mean time 
to the first detection of malignant cells of 6 .8  weeks (S.D.  2.22) .
In the saline group the 47 animals had a mean time of 7.19 weeks (S.D.  2 .36) 
to the production of malignant cells.
From these figures it can be seen that when the results for the animals 
producing malignant cells are examined there is no significant difference between 
the control groups and the experimental groups, nor between the two experimental 
groups, when the carcinogen remains in position.
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D) The length of Hme from the implantation of the carcinogen to the 
earliest evidence of invasion.
The experiment designed to determine the time from the carcinogen 
implantation to the first evidence of invasion, and the effect thereon of B .C .G . 
immune stimulation and A .L .S . immune suppression, was divided into two parts : 
the first part included mice from the groups S.T. 1 and S.T. II and in this section 
the carcinogen remained in position throughout. Details of the results are shown 
in Table X .
In this experiment, of those animals receiving N .H .S . ,  32 produced
evidence of invasion and were included In the statistical analysis which gave a
mean time to invasion of 13.9 weeks (S .D . 2 .23 ).
O f the animals receiving A .L .S . 29 produced evidence of invasion with a
mean time to invasion of 13.4 weeks (S .D . 1.93).
In the group receiving B .C .G . the mean time to invasion, of the 21 animals 
producing evidence of invasion, was 16.47 weeks (S .D .2.4).
The 25 animals included in the saline control group had a mean time to 
invasion of 14,28 weeks (S .D . 1.79).
From these figures it can be seen that, when the carcinogen remains in 
position and tumours are produced over a relatively short period there is no evidence 
of any significant acceleration or delay of invasion by A .L .S . or B .C .G . when 
compared to each other, or to the control groups.
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The second part of this experiment included animals from the groups 
L .T . 1 and L .T . 2 in which the carcinogen was removed on the first 
detection of malignant cells by cytological examination. The results are 
shown in detail in Table X I.
In this experiment, of the animals receiving N .H .S . 23 were suitable 
for statistical analysis having produced evidence of invasion. In these animals 
the mean time to invasion was 34.0  weeks (S .D . 4 .0 ) .
O f the animals receiving A .L .S . ,  28 produced evidence of invasion 
and statistical analysis showed a mean time to invasion of 26 weeks (S .D . 5 .2 ) .
The B .C .G . group contained 15 animals that produced evidence of invasion 
with a mean time to invasion of 40 .9  weeks (S .D . 6 .0 ) ,
In the saline control group the 22 animals included with evidence of 
invasion had a mean time to invasion of 34.8 weeks (S .D . 3 .78 ).
These results show that when the influence of the carcinogen is removed 
there is a significant shortening of the length of time to the occurrence of 
invasion when the animals receiving A .L .S . are compared to the control groups 
(P < 0 .0 2 ), and that there is a significant lengthening of the length of time to 
the occurrence of invasion when the group stimulated by B .C .G . is compared 
to the control groups (P < 0.02 ) .  In this experiment it is also demonstrated that 
the difference between the A .L .S . immunosuppressed group and the B .C .G . 
immunostimulated group is highly significant (P < 0 .0 0 1 ).
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E) The time from detection of the first malignant cells to the detection of 
invasion.
This experiment to determine the length of time from the detection of the 
first malignant cells to the first evidence of invasion, and the effect on this of
A .L .S . or B .C .G . treatment was divided into two parts.
In the first part, using the animals from the S.T. I and S.T. 11 groups, 
in which the carcinogen remained in position throughout, the following results 
were obtained (Table X II) .
O f the animals receiving N .H .S . ,  32 were available and these showed a 
mean time of 7.15 weeks (S .D . 2 .87) from detection of first malignant cells till  
the occurrence of invasion.
29 animals receiving A .L .S . had evidence of invasion and the mean time 
from the detection of first malignant cells to Invasion was 6 .6  weeks (S .D . 2 .4 ) .
In the group receiving B .C .G . the 21 animals had a mean time of 9 weeks 
from first malignant cells to the earliest detection of invasion.
O f the saline control group the 25 animals which produced evidence of 
invasion had a mean time of 7 .4  weeks (S .D . 3,18) from first malignant cells to 
the earliest detectable signs of invasion.
These results show a slight lengthening of the time from the first detection 
of malignant cells to the earliest signs of invasion in the group receiving B .C .G . , 
compared to both the controls and the A . L.S. group but this difference was not 
significant (P < 0 .2  ) .
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In the second part of this experiment animals from groups L.T. I and 
L.T, 2 , in which the carcinogen was removed on the detection of the first 
malignant cells, were used.
The details of the results are given in Table X I11.
O f the animals receiving N .H .S . ,  23 were available, having produced 
evidence of invasion, and in this group the mean time from the detection of the 
first malignant cells to invasion was 27 weeks (S .D . 4 .59 ).
O f the animals receiving A .L .S . ,  28 produced evidence of invasion, with 
a mean time of 18.6 weeks (S .D . 5.18) from first malignant cells to the occurrence 
of invasion.
In the group receiving B .C .G . statistical analysis of the 15 animals that 
produced evidence of rnvasion showed a mean time of 34.3  weeks (S .D . 6 .0 )  
from the detection of the first malignant cells to the demonstration of invasion.
The 22 animals in the saline control group had a mean time of 27 .4  weeks 
(S .D . 5 .0 ) from first detected malignant cells to invasion.
These results further emphasise the effect of B .C .G . and A .L .S . on the 
progression of carcinogenesis from the cytologically malignant in-situ stage to 
the early invasive carcinoma, where the influence of the carcinogen has been 
removed. The reduction in the mean time from the detection of the first 
malignant cells to invasion in the group receiving A . L.S. is significant compared 
to the control groups (P < 0.07 ) .  Contrasting with this^the lengthening of the time 
from the detection of first malignant cells to the occurrence of invasion in the
B .C .G . group compared to the controls is also significant.
The difference in the time from the detection of the first malignant cells to 
invasion when the A .L .S . group and the B .C .G . group are compared is highly 
significant (P < ,0 .0 01 ).
oo
z
2
6
Z
g
oo
$z
o
LU
U
Z
o
u
I—z
zo
oo
o
zg !—' 
u
LU
tuo
s
oet;
LL_
X
LU
CQ
<
OO
u
H -
Z
zo
ooQü
0
zg
r-
U
LU 1  
LUo
Zo
o
>O
LU
Q£
I
C
ro
û
oô
* 0
0
5
o
Z
o
Z
%
4
N
CN
S
8 '
00
CN
00 CO 
CN CO 
•»>
^  W
-L " CN* 
CO CN
CN* CO 
CO CN
8  î ï  
8  S
CN
S
CN
8
—  CN 
CN CO
8*8
CO
CN
OO
X
Z
00
4
o
00
s  52
CO 4  
CN “ C .
52 ^  
8 * 2 '  
é ' S
“ * 4
8
o  :o '
CN
—  5 Îf
i i r f
£ 0 8
tro
00
CN
OO
o
4
hs
CN
s
8
cb"
CN
CD
CO
8  8 '  
8 ' ° '  
8 ' ”  
8 ' 8  
8  8*
8 8'
CN tC  
CN CN
4 *  c b
CN CN
R N
S
o
4
CO
8
CO
CN
N
CO
Nj-
CO
'N '
00
CO
CN
CO
-N"
CN
CN
N f
LO
CO
CO
CO
N On
CN CO
CN CN
CO
LO
Ü
Ü
cû
F) Modification of the hlstopathology by A . L.S. and B .C .G .
Mice from two of the groups of experiments in which the carcinogen had 
been removed, L.T. 1 and L .T . 2 , were used to study the histological patterns 
in the immunosuppressed and immune stimulated animals, to compare these to 
each other and to the control groups, and to determine if  any differences could 
be demonstrated.
In the mice treated with A. L.S. or B .C .G . there was no alteration in the 
histological type of carcinoma produced, these being predominantly w ell- 
differentiated squamous carcinomas with no evidence of any increase in 
undifferentiated tumours in either group compared to the controls. Nor were 
the early types of intra-epithelial lesions altered in any way, being formed by a 
diffuse proliferation of the basal and parabasal cells as in the control groups. 
Underlying these relatively normal epithelia, however, in a few mice,occasional 
solitary aggregates of lymphoid cells and macrophages could be found (Fig. X X IX  )« 
These aggregates were separated from the epithelium by fibrotic connective tissue 
and associated with these cells were mast cells and eosinophil leucocytes. No  
epithelial cells, either viable or degenerate, could be identified by light 
microscopy in these lesions, nor could any keratin debris be found. The intra- 
epithelial lesions that could be classified as definitely pre-invasive, severe 
dysplasia and in-situ carcinoma, were histologically and cytologically similar 
in the experimental groups and in the controls. With this type of lesion there 
was, however, in the experimental groups and controls, variation in the response 
in the underlying tissues. In the immune competent control groups, associated 
with the intra-epithelial lesions there were dense lymphocyte and plasma cell 
infiltrates in the underlying stroma, these infiltrates being closely applied to
mFIG . X X IX . Aggregates of lymphoid cells and plasma cells occasionally 
found underlying relatively normal epithelium.
FIG . X X X . Lymphoid and macrophage infiltrate underlying intra-epithelial 
neoplasia.
the basement membrane. The cellular infiltrates were only apparent at the 
segment of epithelium which had undergone changes suggestive of neoplasia 
even if  this was still intra-epithelial (Fig. XXX ). Associated with the severely 
dysplastic epithelial changes, the lymphoid cells were aggregated in focal clumps 
while underlying the in-situ carcinoma, the cellular infiltrate tended to be more 
diffuse. The adjacent epithelium, normal or with only mild dysplasia, had 
no associated lymphoid cell aggregation.
However, in the experimental group receiving A .L .S . there was a markedly 
reduced chronic inflammatory response so that little difference could be found 
between the stroma underlying the normal or mildly dysplastic epithelium or the 
stroma, underlying segments of epithelium showing definite intra-epithelial 
malignancy, in the stroma underlying both types of epithelium there were 
sporadic lymphocytes and plasma cells, occasionally in small groups, but no dense 
cellular aggregations closely applied to the basement membrane (Fig. X X X I).
In the groups receiving B .C .G . the cellular response was more diffuse, but 
In these areas where there were definite intra-epithelial malignant changes, the 
lymphoid infiltrate was not only intense in the underlying stroma but numerous 
lymphoid cells could be found in the atypical epithelium (F ig .X X X II). Plasma 
cells were also numerous in the underlying stroma. However, the most 
significant changes were segmental lesions where the inflammatory infiltrate was 
so intense, and so involved both the stroma and the full thickness of the 
epithelium, that it obscured the epithelial cells with the result that none could 
be identified either in their normal position nor in the underlying tissue (F ig .X X X III). 
In this type of lesion there were also large numbers of macrophages and the 
appearances suggested a vigorous response to and destruction of, either pre­
invasive or early invasive malignancy.
4 % .
FIG . X X X I . From a mouse receiving A . L.S. : Little evidence of any lymphoid 
infiltrate in the stroma underlying the atypical epithelium.
m
F I G . X X X I I . From a mouse receiving B . C . G .  : Lymphoid cells and macrophages 
in the stroma and in the epithelium.
FIG . XXXI11. From a mouse receiving B . C . G .  The lymphoid and macrophage 
cellular infiltrate has obscured the epithelium.
F I G . X X XI V .  Micro-invasion with the nests of carcinoma cells surrounded by 
lymphoid cells and macrophages.
when micro-invasion and early invasion occurred in the immuno­
competent controls the nests and cords of invasive carcinoma were frequently 
surrounded by large numbers of lymphocytes, plasma cells and macrophages 
(Fig.XXXIV).Fibroblasts also appeared to be increased and there was usually 
moderately increased fibrosis of the sub-epithelial tissues. In association with 
the early invasion lesions, mast cells and eosinophil leucocytes were also
numerous.
In the mice receiving A . L. S ., in those lesions that could be classified as 
showing the earliest evidence of mïcro-invasion there was a marked difference in 
the tissue response to the mîcro-învasion compared to either the control animals 
or to the groups receiving B . C . G .  In this situation there was a markedly reduced, 
mononuclear cell response and those cells that were present were mainly plasma 
cells. Mast cells and eosinophils were also present in reduced numbers. The 
histological picture of the earliest invasion was of thin cords or finger-like  
projections of basal type cells invading into the stroma with little  evidence of 
any cellular response ( F i g . X X X b u t  with a moderate fibrous reaction around the 
advancing lesions.
The earliest forms of micro-invasion in the animals receiving B . C . G .  were 
obscured by the intensity of the inflammatory response in which lymphoid cells 
and macrophages predominated (Fig.XXXVI)and the invading process often 
included degenerating epithelial cells suggesting retardation of the invasion 
(F ig .XX XV II). Where the invading lesions had differentiated to form definite 
squamous epithelium, plasma cells were prominent and eosinophil leucocytes 
and mast cells were also greatly increased. Early fibrosis was also a feature of 
this type of development.
f tf
FIG . X X X V .  From a mouse receiving A . L . S. : Finger-like projections of atypical 
basal cells invading into the underlying stroma with little  evidence of 
cellular response.
F I G . X X X V l . From a mouse receiving B . C . G .  Intense lymphoid and plasma cell 
infiltrate obscuring the early invasive lesions.
ÉFIG . XXXVl  I . From o mouse receiving B . C . G .  Degenerating epithelial 
carcinoma cells associated with an intense lymphoid and 
macrophage infiltrate.
< r,
FIG . XXXVl  11. Advanced invasive carcinoma with only a slight lymphocytic 
response at the periphery.
When definite invasion and tumour formation had occurred there appeared 
to be a marked reduction in the tissue responses in the control group, this being 
represented mainly by a comparatively slight lymphocytic response at the 
periphery of the carcinoma (Fig.XXXVIll).In the A.L .S.  group there appeared to 
be even fewer lymphocytes. In the group receiving B . C . G .  there was a reduced 
response compared to the response B . C . G .  evoked in the earlier lesions, but it 
was increased compared to the control groups and to the A . L . S .  groups with a 
similar sized tumour. In the B . C . G .  group the inflammatory response was also 
mainly at the periphery of the tumour and around small separated tumour cell 
groups.
DISCUSSION.
If an immunological surveillance rnechanism ( 291 ) is operative
in the normal organism its effect should be to protect against small numbers 
of neoplastic cells localised as incipient clonal foci and the development of 
frank neoplasia would then signify the breakdown of the system either 
artific ially by immunosuppression or by old age ( 292, 293 ).
For immunological mechanisms to inhibit the formation and growth of 
clones of malignant cells, the neoplastic cells must be exposed to the host's 
immunological apparatus and there must be sufficient antigenic dissimilarity 
between the neoplastic cells and the host cells to result in an immune response 
being mounted. A further requirement, necessary to prevent the establishment 
of malignant cells, is that the tumour associated antigens should be expressed 
in the early peculations of tumour cells.
Evidence for tumour antigen expression in pre-malignant lesions is provided 
by studies on M . C .  induced skin papillomas in which it has been established 
that the number of papillomas developing in skin in itia lly  treated with 
carcinogen and then grafted to syngeneic mice correlated with the immune 
competence of the recipients ( 294 ), decreased immunological competence
due to sub-lethal irradiation accelerated the appearance of papillomas and 
increased their incidence while immune stimulation with methanol extracted 
residues of B . C . G .  delayed the appearance of papillomas and decreased their 
incidence. It was also reported that the neo-antigens persisted through the 
progression to malignancy and were detectable in the skin carcinomas 
derived from the individual papillomas ( 31 ). This would appear to
invalidate the claim, derived from studies involving transplantation of 
malignant cells, that the immune response must be rapidly mounted to eradicate 
the malignant cells before they become established as tumours, since in the 
usual situation in the development of malignancy the antigens would be present 
in the relatively long pre-invasive phose,and emphasises the fact that experiments 
with transplanted fully malignant cells have little  bearing on the immune 
responses against early in-situ neoplasia, since the insertion of a comparatively 
large number of pre-selected tumours cells into an immunologically virgin 
secondary host is in no way analogous to the formation and growth of a primary 
tumour in its unique micro-environment.
In this situation in which neo-antigens persist from benign into malignant 
lesions, the possibility exists that the shedding of antigenic tumour membrane 
products from the cells of the pre-mo lignant lesions may result in local conditions 
in which are formed antigen-antibody complexes and these might, in turn, abrogate 
any cell mediated response against malignant clones of cells which subsequently 
emerge carrying the same antigens^ thus allowing invasion to take place.
It is also possible that modification of the systemic immune response by the 
released antigen products of the pre-malignant lesions may be such, that any 
malignant clones of cells that emerge carrying the same antigens may be 
protected from destruction, in a similar way in which kidneys transplanted Into 
recipients who have received multiple blood transfusions are protected (295) .
Further studies, investigating the influence of immune status on the progression 
or regression of papillomas, established that not only did a greater number of 
papillomas develop In M . C .  treated mouse skin transplanted to immuno-suppressed
syngeneic mice than occurred in control or immune-stimulated mice, but that 
the immune reactivity of each group of mice correlated with the regression of 
the papillomas, the greatest proportion (71%) regressing in the immune- 
stimulated group, while the lower proportion (30%) regressed in the immune- 
suppressed group (296) .
Papilloma progression to carcinoma in transplanted M . C .  treated skin was 
also influenced by the immunocompetence of the host : the time of appearance of 
squamous cell carcinoma was shorter and the final incidence higher in immuno- 
suppressed mice (296).
These studies established that early populations of methyl-cholanthrene 
transformed cells have neo-antigenic specifities capable of inducing an immuno­
logical rejection reaction, but these effects have only been detected by 
transplantation manipulation which probably serves to call attention to the neo­
antigens.
Investigations on the effect of immunosuppression on the various stages of 
skin carcinogenesis, in which transplantation was not used, presented a pattern 
contradictory to the preceding studies. Short-term immune impairment by
A . T . S .  did not modify the initiating effect of topical D . M . B . A . ,  nor the 
subsequent response to promotion with croton oil skin painting, as measured by 
tumour incidence, latent period and degree of progression to malignancy compared 
to normal controls ( I I  ).
Similar experiments comparing the effects of autografting M . C .  treated 
skin with undisturbed animals suggested that while they remain undisturbed the 
developing lesions do not stimulate an immune response which w ill eliminate 
the developing malignant cells, questioning the contribution of immune mediated
rejection in-situ. The postulate here is that the increased vascularity 
associated with the inflammatory response to the trauma of transplantation 
increases the numbers of lymphocytes passing through the tissues and brings 
these into contact with the neo-antigens in the developing malignant cells 
thus initiating an immune response, and that in the undisturbed lesion this 
does not happen (147).
It is, however, equally possible that the inflammatory response associated 
with transplantation disrupts the micro-environment in which the in-situ lesion 
is developing and that if this contains free antigen or antigen-antibody 
complexes, which are blocking the cell mediated response to the incipient 
neoplasm, then disruption of this micro-environment may cause dilution of the 
complexes by oedema, their removal by the Increased flow of tissue fluids, or 
alteration In the antigen-antibody ratio by macrophage or polymorphonuclear 
leukocyte digestion of the antigen or the complexes ; by whatever means,the 
loss of the free antigen or complexes may allow the lymphocytes to destroy 
the neoplastic cells.
This explanation of the course of events is in many ways more tenable 
than the concept that in-situ lesions do not evoke a response and thus lymphocytes 
do not gain access to the lesion to be stimulatec^ since the histological examination 
of in-situ lesions often demonstrates an intense lymphoid exudate closely applied 
to the lesion (24,  27). It should be noted, however, that in common with 
the lymphoid response there is also a marked plasma cell response with the 
presumed production of antibody capable of blocking cell mediated responses.
Similar considerations may apply to M . C ,  induced hyperplastic breast 
nodules which are immunogenic and are rejected on transplantation to syngeneic 
mice but which appear to arouse little  reaction while in-situ In the mammary pad 
( 297 ) .  A  complication here, however. Is that It is claimed that the
mammary pad Is an immunologically prevlllged site ( 298 ).
Contradictory results are reported in two experiments investigating the 
effect of A . L . S .  on the development of pre-malignant liver lesions ( 13, 153 ).
In the first experiment ( 1 3  ) the incidence of pre-neoplastic lesions
was increased whereas in the second ( 153 ) no difference in number or
size of the precancerous foci could be detected. However, in this second group, 
in one experiment in which animals were treated with A . L . S .  to the stage where 
precancerous lesions should have been present, and then left untreated, there 
was a much higher incidence of tumours over the controls.
In our experiments In which the carcinogen remained in position we failed
to demonstrate any difference in the length of time to the detection of the first
i
malignant cells and to the time of formation of either severe dysplasia or in-situ 
carcinoma In either the immune stimulated or immune suppressed animals when 
the groups were compared to each other or to the controls. These findings 
are in agreement with the experiments in which papillomata are allowed to 
develop undisturbed and in which no evidence of any effect of alteration of the 
immune response could be demonstrated (147 ).
Nor could we find any difference in the length of time for the progression 
of severe dysplasia or in-situ carcinoma to invasive carcinoma, associated with 
either immune stimulation with B . C . G .  or immune suppression by A . L . S .  These
experiments were also in agreement with the experiments in skin.carcinogenesis 
in which the lesions are allowed to progress undisturbed.
The apparent finding of an increased number of tumours in the A. L . S .  
group of the S.T.  experiments (Table 1) compared to the B . C . G .  group, and 
the controls, suggests an effect of immune suppression or immune stimulation, but 
if  the number of micro-invasive carcinomas is added to the number of tumours, 
the total number of invasive lesions in all groups becomes almost equal and 
suggests a modest acceleration of tumour growth by A . L . S.  and tumour retardation 
by B . C . G . ,  which is probably exaggerated by the short length of the experiment. 
This would be In agreement with those experiments in which the carcinogen is 
injected and in which only a modest increase in the latent period could be 
demonstrated, the ultimate tumour numbers being the same no matter what 
immunological manipulations were used.
This point is emphasised by the finding that in the S.T.  experiment there 
was no significant difference between the various groups in the number of mice 
in which the cervical epithelium returned to normal. At the termination of 
the experiments virtually no animals had normal epithelium, meaning that in 
these animals there is a continuing potential for the development of carcinoma 
and provides a possible explanation for those experiments in which the injection 
of relatively large amounts of carcinogen ultimately gave rise to the same 
number of tumours, in spite of immune stimulation, if the experiments are 
continued long enough ; it is that the malignant potential of the transformed 
cells outlasts the immune stimulated state and as this wanes outgrowth of the 
invasive lesion occurs.
In these experiments, however, the Influence of the continuing presence of 
the carcinogen raises several questions.
The immunosuppressive action of methyl cholanthrene on humoral antibody 
has been established ( 299, 300 ) and it has been substantiated that the 
carcinogenic dose is sufficient to depress immune responses ( 300 ) and that
the effect of a single dose resulted in prolonged immunosuppression over a period 
of several months ( 301 ). Administration of small doses, either by
subcutaneous injection or skin painting led to a cumulative effect. ( 131 ). 
Evidence that methyl cholanthrene also exerts a suppressive effect on cell 
mediated immunity,was provided in studies demonstrating increased survival of 
male to female skin grafts and accelerated growth of first transplant generation 
sarcomas In treated mice (302, 303 ).
Interference with the cellular rather than the humoral responses Is more 
likely to be a significant factor in modifying carcinogenesis and a correlation 
between methyl cholanthrene induced cellular immunosuppression and its 
carcinogenic effect has been demonstrated (303 ).
These effects have all been demonstrated systematically using serum and 
circulating lymphocytes but little  is known about the local effects of the 
carcinogen. Even when carcinogen administration does not lead to systemic 
immunosuppression a local effect on the immune responses may prevent the 
destruction of nascent tumour cells in the area of carcinogen application. In 
this respect, it is noteworthy that it has been shown that subcutaneous tissue 
transplanted from the site of injection of benz (a) anthracene or dibenzo (ai) 
pyrene accelerates epidermal carcinogenesis. If a phenomenon such as local
immunosuppression actually occurs during chemical carcinogenesis then the 
addition of a systemic immunosuppressive might not be expected to alter 
markedly the degree of tumour induction. Similarly generalised B . C . G .  
immune stimulation might not overcome local immunosuppression although 
the ability of B . C . G .  to overcome systemic carcinogen-induced immuno­
suppression has been demonstrated ( 3 0 4  ).
The immunosuppressive component of chemical carcinogenesis may explain 
why the effects of thymectomy and A . L . S .  immunosuppression are no more 
dramatic in increasing tumour incidence : this probably depends on the 
differential between the immunosuppressive action of the chemical carcinogen 
and the residual rejection potential after thymectomy or A . L.S. treatment.
It should be noted, however, that the same dose of M . C . A .  can have a 
markedly different carcinogenic effect in different strains of mice (139 ) 
probably due to genetic differences in the susceptibility to carcinogenesis by 
this chemical, and that the demonstrable effect of A . L . S .  in increasing tumour 
incidence is inversely related to the susceptibility of the strain of mice to M . C . A .  
In strain 1 mice, in which M . C . A .  produces limited numbers of tumours, A . L . S .  
will greatly increase the incidence of tumours, whereas in C^H strain, in which 
the same dose of M . C . A .  w ill produce tumours in virtually 100% of mice, any 
effect of A . L . S .  w ill be lost in the overwhelming effect of M . C . A .  In 
experiments in C^H mice, using a technique for M . C . A .  induction of carcinoma 
of cervix similar to ours, and following the progress with exfoliative cytology, 
the rate of malignant transformation was so rapid that in the short time taken to
process and examine the cytology specimen used in the detection of the first 
malignant cells, and killing the animal (< 24 hours) invasion occurred and 
could be recognised in the post mortem specimen. Obviously in this type 
of situation no effect of systemic immunosuppression on carcinoma formation 
could be demonstrated (2 8  ). In Swiss mice such as are used in our experiments 
a long pre-malignant phase can be recognised ( 305 ),
Another demonstration of the effect of A . L . S .  in a situation where a 
limited number of tumours develops is given in d single strain of mice 
(C57BL/6 X  BALB/c) Fl in which increased tumour production with A . L . S .  was 
detected in the group receiving a low dose of M . C . A . ,  compared to controls 
receiving the same dose ( 140 ).
These results suggest that A . L . S .  might potentiate tumour production 
only under these circumstances where a limited oncogenic effect of M . C . A ,  is 
demonstrated.
In most studies the effect of B . C . G .  on chemical carcinogenesis has been 
temporary(8,286)and in several of the more encouraging studies an apparent 
decrease in tumour incidence may be due to a delay in the appearance of 
tumours that would have developed, if  the life of the animal had not been 
cut short by the short duration of the experiment ( 272 ). This would be in 
agreement with our S.T.  experiments in which at the termination of the experiment, 
despite B . C . G .  immune stimulation, the epithelium was still of a type -  severe 
dysplasia or in-situ carcinoma -  with the potential to produce invasive carcinoma.
Many studies on the effect of B . C . G .  on chemical carcinogenesis have 
been performed with high doses of chemical carcinogenesis capable of producing
tumours in 100% of animals in a short time. It is possible with the high dosage 
of carcinogen used in these experiments, that sufficient carcinogen to induce 
neoplasia may remain unmetabolised at the site of infection, after the 
immunostimulatory effects of B . C . G .  have ceased. If the immunosuppressive 
effect of chemical carcinogenesis is of any significance then high doses of 
these carcinogens could both induce the formation of malignant clones and 
prevent their elimination. Although it is known that B . C . G .  can reverse 
the immunosuppressive effects of certain carcinogens it is not known how long 
reversal lasts, since all the experiments demonstrating the effect were of 
short duration ( 304 ) ,  and with the high doses used in some experiments it 
is possible that some immunosuppressive effect may remain after the B . C . G .  
stimulation has lessened. It is also not known if  systemic B . C . G .  can overcome 
any local immunosuppressive effects of a high concentration of carcinogen, 
although if  injected admixed with the carcinogen a marked decrease in the 
incidence of tumours resulted ( 306 ) ,  suggesting that local events were more 
important than the systemic events. Similar effects have been demonstrated 
with intramuscular injection of an admixture of B . C. G.  with the mouse sarcoma 
virus of Maloney (M S V- M) which suppressed the development of the tumour at 
the injection site (307 ), Protection was increased if the animals were 
previously immunised with B . C . G .  In this situation,however, although the 
immune response may aid the host defence against neoplasia, it is possible 
that B.CG.  might act by limiting the infection and persistance of the 
oncogenic virus, since animals infected with B . C . G .  resist viral infections 
(8 ,3 0 8 ), and the intravenous injection of tuberculin can stimulate the release 
of interferon in B . C . G .  Immunised mice.
A situation analogous to this might exist with regards to the chemical 
carcinogenesis since it is known that macrophages and monocytes posses at 
least one enzyme that catalyses the metabolism of polycyclîchydrocarbon 
carcinogens (309 ). By increasing the enzyme levels within these cells
B . C . G .  stimulation could greatly accelerate the active conjugation or excretion 
of these compounds so reducing the carcinogenic potential, and no immunological 
processes need necessarily be involved.
The experiments of Lappe ( 294 ) avoided the effects of systemic immuno­
suppression by transplanting the methyl cholanthrene treated skin of syngeneic 
recipients. Injection of methanol extraction residues of B . C . G .  delayed the 
appearance of macroscopic papillomas and decreased their incidence.
Histological examination revealed a number of sub-macroscopic papillomas 
in excess of the controls, and many of these papillomas were associated with 
localised lymphocytic infiltrates. The incidence of carcinomas could be 
correlated with the total number of days that mice bore papillomas suggesting 
that prevention of carcinoma formation depended on the elimination of pre- 
malignant lesions. In this type of experiment, however, the trauma 
associated with transplantation,adds its own problems to the difficulties of 
interpreting events.
In an attempt to reduce the effects associated with the continuing presence 
of the carcinogen in our second group of experiments, the L.T.  group, we removed 
the carcinogen and to avoid the problems associated with short term experiments 
we allowed these experiments to continue for one year after the implantation of 
the carcinogen.
in these experiments a divergent effect of A . L . S .  and B . C . G .  can be 
seen. In the L.T.  group 1 there was a significant difference in the number of 
mice developing tumours between the A . L . S .  group, 12 but of 18 mice, 66% , 
and the group receiving B . C . G .  6 out of 21 mice, 28.5%.  In contrast to 
the S.T. experiments, however, as the stages of carcinogenesis are added 
together then the disparity becomes more marked. When the numbeisof mice 
with micro-invasive carcinoma are included it can be seen that the difference 
in the numbers of mice developing invasive lesions, between the groups 
receiving A . L . S . ,  15 out of 18 mice, 83%, and the group receiving B . C . G . ,
7 out of 21 mice, 33% , becomes more marked while in the S.T. group the 
difference became less marked. This contrasting effect of A . L . S .  and B . C . G .  
when the carcinogen had been removed, is emphasised when the number of mice 
with all invasive or potentially invasive lesions are included at the termination 
of the experiment. It can be seen that 17 out of 18 mice, 94%, receiving 
A. L . S .  had either developed, or had the potential to develop, invasive 
carcinoma, whereas in the group receiving B . C . G .  only 10 out of 21 mice, 47 .5 % , 
were in this category. The control groups were intermediate to the two 
experimental groups. This contrasts also with the S.T.  experimental groups in 
which, at the termination of the experiment, the numbers of invasive or potentially 
invasive lesions were virtually identical in all groups, experimental or control.
Further emphasis for the divergent effects of A . L . S .  and B . C . G .  in the 
L.T.  experiments are found in group L.T.  1 in the figures for the numbers of 
cervices which had returned to normal at the termination of the experiment ; in 
the A. L . S.  group only 1 out of 18 mice had an apparently normal cervix, whereas
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in the B . C . G .  group 9 out of 21 mice had reverted to normal. In the control 
groups, 4 out of 16 mice, 25%, and 4 out of 18 mice, 22%, had returned to 
normal from a potentially invasive epithelium.
In L.T.  group 2, in which A . L . S .  and B . C . G .  were started on the day 
of removal of the carcinogen, the figures for all the groups were similar to those 
of L.T.  1, Tables V8tVI, and no effect could be demonstrated, of the delay in 
giving A . L . S .  or B . C . G .
The experiments L.T.  1 and L.T.  2 demonstrate that when the influence of 
the carcinogen is removed, A . L . S .  or B . C . G .  have a marked effect on the 
progression or regression of potentially invasive epithelium at normal tissue 
interfaces. In this situation A . L . S .  prevents the reversion of the epithelium 
to normal and promotes the development of invasive carcinoma, while B . C . G .
increases the number of cervices reverting to normal in comparison to the controls
/
and the A . L .S .  group, and decreased the number of carcinomas forming. This is 
also in contrast with the situation in the S.T.  experiments where at the termination 
of the experiment in the animals receiving B . C . G . there was little  evidence of 
any reversion to normal.
In L.T.  group 3 and 4 an attempt was made to further reduce the influence 
of the carcinogen by waiting three months after removal of the carcinogen and 
sub-dividing the mice into two experimental groups, L.T.  group 3 with 
cytological evidence of in-situ malignancy and L.T. group 4 with cytological 
evidence of early invasive carcinoma but with no visible or palpable tumour.
In L.T.  group 3 the results, although similar to those of groups L.T.  1 and 
L.T.  2,  were more divergent, and demonstrated a marked effect of A . L . S . ,  by 
the increased incidence of tumours, the maintenance of in-situ malignancy and
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a corresponding failure of the reversal of the epithelium to normal, with none 
of the mice receiving A . L.S, having a normal epithelium at the termination of 
the experiment.
O f the animals receiving B . C . G .  only 3 out of 16 mice, 18.7%, formed 
tumours and 10 out of 16 mice, 62 .5% , reverted to a normal epithelium, while 
in the control groups receiving N . H . S . ,  3 out of 20 mice, 15%, or saline, 4 
out of 19 mice, 21%, reverted to normal.
In L.T.  group 4 the effect of immune stimulation and immunosuppression 
on early invasive carcinoma was demonstrated. As might have been e>qDected, 
the incidence of tumours developing in the control groups was higher than in the 
other L.T.  groups being 60% and 62,5%  in the N . H . S .  and saline groups, 
respectively.
In the experimental group receiving A. L . S .  13 out of 15 mice, 86 .6% , 
ultimately developed tumours and 1 out of 15 mice, 6 .6 % , had a micro-invasive 
carcinoma. One mouse had an in-situ pre-invasive lesion.
I
O f the group receiving B . C . G . , 2 out of 15 mice, developed tumours, and 
3 out of 15 had micro-invasive carcinomas, giving an incidence of 5 out of 15 mice 
with definitely invasive lesions. 3 out of 15 mice had either severe dysplasia or 
in-situ carcinoma but the most interesting observation was that, even when 
starting with an early invasive lesion, 7 out of 15 mice had at the termination 
of the experiment either mild dysplasia or almost normal cervical epithelium.
This suggests that even with early invasive carcinoma occurring at natural epithelial 
stomal junctions, B . C . G .  could be effective in preventing tumour development 
and could cause reversal of the malignant epithelium to almost normal. In this 
group none of the control mice reverted to normal, although some did appear to 
regress to an in-situ stage of malignancy.
I J /
In view of the divergent effects of A , L . S . and B . C . G .  on potentially 
invasive epithelium in the L.T,  experiments,and since in the N . H . S .  control 
groups in L . T . l  and L . T . 2, 4 out of 16 mice and 3 out of 20 mice, in these 
groups respectively reverted to normal, and in the same groups 4 out of 18 
mice and 4 out of 19 mice receiving saline reverted to normal, it is 
suggested that this elimination of the potentially invasive carcinoma with 
reversal to normal are due to immunological processes occurring in the 
unstimulated mice with undisturbed pre malignant lesions. This is 
in contrast to other experimental findings ( 1]^ 147 ) ,
Treatment of mice with B . C . G .  ( 8 272 ) O'" Freund's adjuvant ( 3 ] 0 )  
has been shown to result in some inhibition of tumour induction and to delay 
the appearance of tumours although not apparently affecting the final 
incidence.
Immunosuppression by thymectomy ( 125 ) t  A . L . S .  ( 23, 129 ) and 
azathioprine;( 31 1 ) ,  has been shown to increase the incidence of tumours
in mice,and reduce the latent period.
It has been suggested (8) that B . C . G .  given at the onset of carcinogenesis 
inhibits the outgrowth of the tumour but is without effect on the early processes. 
No evidence, however is given for this statement except that the latent 
period, to the discovery of a palpable tumour, is prolonged. This might be 
due to the selection for slow growing weakly immunogenic tumours rather 
than the inhibition of all tumours, or to the prevention of formation of or 
elimination of the early stages of neoplasia. On the other hand all the forms 
of immunosuppression used, thymectomy, A.LS.  or a^athioprine have shortened 
the latent period to tumour formation but have not always increased the
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încîdence of tumours. No information îs available on the effects of A . L . S /  
or B . C . G .  on the stages preceding the detection of a palpable tumour.
A.LoS.  orB.CpG,  could produce the above effects of the latent 
period to the production of a palpable tumour by acting at the stage of the 
production of the first malignant cells, by acting on the stage of in-situ malignancy^ 
or by acting at the later stages of invasion or tumour growth.
In the studies in the L.T,  experiments of the effects of A . L . S .  on B . C . G .  
on the length of time from the implantation of the carcinogen to the detection 
of evidence of invasion the results, .table X I show that, in contrast, to the
S.T.  experiments, A . L . S .  considerably shortened this time while B . C . G .  
increased the lengthof this latent period.
Similar results were obtained when the length of time from the first 
detection of malignant cells to the time of invasion were investigated (table XI I I  ) .
Here again A . L . S ,  shortened, and B . C . G .  lengthened, the pre-invasive stage 
compared to the controls and to each other.
These results suggest that AL.S. and B . C . G .  have some effect on the early 
stages of neoplasia and invasion and do not merely act in the later stages 
of tumour formation. Unfortunately we found it  Impossible to devise an experiment, 
using this model, which would allow us to implant the carcinogen for the minimum time 
that would result in a consistent yield of malignant changes, while allowing 
the removal of ihe carcinogen at some stage before the formation of malignant 
cells. This might then have allowed some insight into the effects of A . L . S .  
or B . C . G .  on tbe length of time to the emergence of the first malignant cells 
without the continuing effect of the carcinogen. In our attempts at achieving
this state no reliable indicator of any very early stage in the neoplastic process 
at which the carcinogen could be removed resulting in a consistent yield of 
tumours, to which the A . L . S .  group or B . C . G .  group could be compared 
was obtained. Nor did the implantation of the carcinogen for a short 
fixed time give the necessary reproducible tumour yield although numerous 
different short periods of implantation were tried. This would have been the 
ideal test for the effect of A . L . S .  or B . C. G.  on early carcinogenesis and 
the emergence of clones of malignant cells.
Conflicting observations of the efficiency of B . C . G .  in preventing 
tumour development and of A . L . S .  in facilitating tumour formation may. 
depend on different schedules of administration.
Pretreatment with B . C . G .  has been effective in some studies though 
not in others, and a protective effect has been observed when B . C . G .  has 
been given before or at the time of exposure to the carcinogen, or after 
exposure to the carcinogen but before the appearance of a visible tumour.
A significant delay in the appearance of fibrosarcomas was recorded (286)  
when B . C . G .  was given to mice either 2 weeks before or 2 weeks after 
methyl cholanthrene injection, but if the B . C . G .  was delayed until 50 days 
after the methyl cholanthrene, at which time the first tumours were detectable, 
the appearance of fibrosarcomas In the remaining animals was accelerated.
B . C . G . ,  the same day as the carcinogen, dimethylbenz (a) anthracene, by 
mouth, delayed the appearance of mammary carcinomas, but if  the B . C . G .  was 
given to rats already bearing primary tumours the appearance of secondary
tumours was accelerated ( 287 ),
Similar effects have been found with variations in the timing of A.L.S, '  relative 
to the carcinogen ( H , 150 ) ,
in our S.T,  experiments no effect of the variation of the timing of the A L.S , 
or BoC,G,  administration at tbe various stages of carcinogenesis could be 
demonstrated. In the L.T,  experiments 1 and 2 again there was no significant 
difference In the numbers of tumours developing, nor the numbers of early 
invasive or pre invasive lesions when the different forms of treatment were 
compared to their counterpart in the other groups.
In the L . T . 3 experiment in which the A . L . S .  or B . C . G . were given three months 
after the removal of the carcinogen the effect of A . L . S .  was slightly more 
marked than in the L . T ,1 and 2 experiments as was the effect of B . C . G ,  when 
compared to the similar groups in experiments L . T . l  and 2.
In the experiment L . T . 4,  when A . L . S , or B . C . G ,  were given to early rvasîve 
carcinomas, A . L . S .  greatly accelerated tumour formation and B . C . G .  caused reversal 
of the early invasion.
This suggests that although immune responses may be active in the early stages 
of neoplastic transformation that the maximun systemic response may occur immediately 
the basement membrane breached and invasion into the underlying stroma occurs.
If the B . C . G ,  or A . L . S ,  is given at this time, to augment or depress the natural 
response then maximum effects might be obtained.
Histological examination of the tissues provides some histopathologîcal basis for the 
preceding observations.
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In the stroma underlying the pre cancerous and early cancerous lesions there 
was an Intense cellular stromal reaction In the groups receiving B.C.G. *  
compared to the groups receiving A . L . S ,  where the response was greatly 
reduced.
This disparity was even more marked in the stages of early invasion 
where the groups of invasive cells, in the B . C . G ,  stimulated animasi were 
frequently surrounded by masses of lymphocytes and macrophages, contrasting 
sharply with the A . L . S.  suppressed animals in which finger like projections 
of invasive cells often appeared to evoke n o  stroma I response, or a very reduced 
response.
When tumour formation occurred then in both groups the stromal response 
was similar being often reduced to small aggregates of small lymphocytes.
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CONCLUSIONS
In experiments on the effects of immune stimulation and immune suppression 
in chemical carcinogenesis, account must be taken of the continuing presence 
of the carcinogen. Divergent effects of immunosuppression and immune stimulation, 
where any effects of the chemical carcinogen are reduced, can be demonstrated.
Whether the main effect of the carcinogen is local or systemic is arguable 
but our experiments would suggest that local events are paramount and that 
against these the alterations in the systemic immune responses are of relatively 
little consequence.
Our findings also suggest that where the effect of the carcinogen is removed 
then alterations in the Immune status of the host wil l  affect the early neoplastic 
processes, especially the duration of the in situ malignancies, as well  as the 
later stages of turnorigenesis, although the effect of B . C . G ,  on micro invasive 
carcinoma suggests that a maximal host response may naturally be occurring at 
this stage. This is also supported by histological studies where the cellular response 
is most intense around the B . C . G .  stimulated mice with micro invasive lesions.
We disagree with those findings which suggest that întra epithelial malignancies 
do not evoke an immune response capable of retarding its progression and growth, or 
of mediating its regression, and provide an alternative interpretation of the events 
responsible for the rejection of transplanted in situ malignancies. Again our 
findings appear to be supported by histopathologîcal findings.
Our demonstration, at the termination of S.T.  experiments, of the presence of 
epithelium with the potential to produce invasive carcinoma provide a basis for the 
results obtained in other experiments on chemical carcinogenesis of short duration, 
where immune stimulation delayed but did not prevent tumour formation.
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